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Figure 1: Structures of vitamin E components.  
 
1 Introduction 
1.1 Vitamin E  
1.1.1 Vitamin E isomers and related structures  
Evans and Bishop first described in 1922 the relevance of vitamin E in reproduction of rats 
(EVANS & BISHOP 1922), which characterized this group of tocopherols (TOH) and tocotrienols 
(T3) including their α-, β-, γ- and δ-isomers as a vitamin. Nowadays the German Society of 
Nutrition (Deutsche Gesellschaft für Ernährung, DGE) recommends a daily intake of 
12-15 mg/d vitamin E for adults, which should be higher during pregnancy (13 mg) and 
breast feeding (17 mg). Generally the recommended intake of vitamin E correlates with the 
amount of poly unsaturated fatty acids (PUFAs) in food: 1 g of diene fatty acid or rather 
diene equivalent requires a 0.5 mg RRR-α-TOH intake.  
Vitamin E belongs to the group of fat-soluble vitamins and occurs dominantly in oily plants; 
therefore nuts, seeds and oils are vitamin E rich sources. Almonds, hazelnuts, germ oil, 
sunflower oil mainly contains high amounts of α-TOH while walnut, palm oil and soybean 
predominantly contains γ-TOH (CARDENAS & GHOSH 2013). Tocotrienols are widely distributed 
in some cereals, in palm oil and rice bran oil. Additionally coconut oil, cocoa butter, 
soybeans, barley and wheat germ are relevant natural sources for T3s (WONG & 
RADHAKRISHNAN 2012). Whereas vegetables and fruits – except dried apricots, some legumes, 




 Figure 2: α-Tocopherol domains. Modified (BIRRINGER  
 et al. 2003; NEUZIL et al. 2002) 
 
 
avocado and green olives – contain less vitamin E analogues (DUTTA & DUTTA 2003). The 
amount of vitamin E isomers contained in food depends on several factors such as growing, 
harvesting and proceeding conditions (refining, cooking) (CHUN et al. 2006; DUTTA & DUTTA 
2003). 
In detail the term vitamin E is defined as a mixture of isomers, which can be distinguished 
mainly into TOHs, T3s and vitamin E-related structures named tocomonoenols and marine 
derived TOHs (MDT) which are synthesized in cold water adapted organism (FUJISAWA et al. 
2010) based on saturation level of the C16 side-chain (Figure 1). Tocopherols are 
characterized by a saturated phytyl side-chain whereas tocomonoenols, MDT and T3 are 
unsaturated at either the terminal isoprene unit or have three double bonds within the side-
chain (KRUK et al. 2011; ZINGG et al. 2010b). Each vitamin E subgroup includes further four 
different isomers namely α, β, γ and δ classified depending on the methylation pattern of 
the hydroxychromanol ring system. Methylation may occur in either of the following 
configurations: (α) 5, 7, 8; (β) 5, 8; (γ) 7, 8 and (δ) 8. Tocopherol and T3 biosyntheses differ in 
the side-chain transferring enzymes: homogentisate (HGA)-phytyl transferase and 
HGA-geranylgeraniol transferase, respectively, which are responsible for the degree of 
saturation of the side-chain. Since HGA-phytyl transferase seems to be involved in the 
formation of tocomonoenols, TOHs are probably their precursors and not T3s (KRUK et al. 
2011). The natural form of vitamin E isomers occur in RRR configuration, whereas the 
synthetic form of TOHs consists of an equal racemic mixture of the eight stereoisomers 
depending on the orientation of the three chiral centers: RRR, RSR, RRS, RSS, SRR, SSR, SRS, 
SSS, but there are only two possible stereoisomers for T3 isoforms (BRIGELIUS-FLOHÉ & TRABER 
1999; CARDENAS & GHOSH 2013; HACQUEBARD & CARPENTIER 2005). Within the group of vitamin E 
RRR-α-TOH is assigned as the most potent member. Hence the vitamin E activities of the 
other isomers were calculated as effect equivalents (tocopherol equivalents, TE [%]) 
compared to RRR-α-TOH: β-TOH 50%, γ-TOH 10%, δ-TOH 3%, α-T3 30% β-T3 5% (BIESALSKI et 
al. 2002). Properties of vitamin E are related to its molecular structure which can be divided 
in three functionally distinct domains: 
the functional domain (I), the signaling 
domain (II), the hydrophobic domain 
(III), as shown in Figure 2 for α-TOH. 
Domains I and II are responsible for the 
biological activity and domain III, the 
side-chain, is characterized as passive 
domain responsible for the 
hydrophobicity of vitamin E and 
connects it thereby to lipoproteins and membranes (NEUZIL et al. 2002). The redox activity of 
domain I is related to the hydroxyl group or other substituents at position C6 at the 
chromanol ring. Modifications at C6, acetylation or succinylation, vary apoptotic effects of 
the compound (BIRRINGER et al. 2003). The methylation pattern on the chromanol ring 
comprises the second domain and is possibly involved in protein phosphatase (PP) 
2A/protein kinase (PK) C signaling of vitamin E.   
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1.1.1.1 α-Tocopherol  
Until today further diverse functions of vitamin E with have been reported that are 
attributed to α-TOH. In early years of α-TOH research the main focus was on its radical chain 
breaking and radical scavenging capacity which protects cellular membranes, lipoproteins 
and other lipid-rich compartments (KOHLMEIER 2003) directly against lipid peroxidation. This 
identified α-TOH as a natural antioxidant (for further information see Chapter 1.1.4). For the 
first time Angelo Azzi provided evidence that next to its antioxidative capacity α-TOH has 
distinct properties. These so-called non-antioxidative features regulate several cell functions 
via signal transduction, modulation of nuclear receptors, and modulation of gene and 
protein expression (AZZI 2007). Based on these diverse α-TOH functions in vitro a role as a 
therapeutic agent for several serious diseases in Western industrialized countries such as 
diabetes, cardiovascular disease including atherosclerosis, and cancer was considered. 
Therefore investigations in multiple animal and human intervention and observation studies 
followed in the next decades; unfortunately with mostly disappointing results. Regulatory 
functions of α-TOH and an overview of the main important human studies are given in 
Manuscript II (page 42).  
  
1.1.1.2 Tocotrienols  
Next to the TOHs the four T3s are important vitamin E isomers with comparable and 
sometimes even stronger biological activities compared to TOHs. It was shown that T3s can 
alleviate α-TOH deficiency symptoms (SEN et al. 2007). Key functions of T3s are their 
antioxidative, antiatherogenic, anticancer, antidiabetic, antiinflammatory and 
neuroprotective properties (SEN et al. 2007; WONG & RADHAKRISHNAN 2012). Additionally T3-
specific effects such as the suppression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase activity (PEARCE et al. 1992) which results in decreased cholesterol synthesis 
are known.  
Apart from well known T3 isomers, α-, β-, γ-, δ-T3, Qureshi et al. identified two new T3 
compounds 15 years ago, named desmethyl T3 [3,4-dihydro-2-methyl-2-(4,8,12-
trimethyltrideca-3’(E),7‘(E),11‘-trienyl)-2H-1-benzopyran-6-ol] and didesmethy T3 
[3,4-dihydro-2-(4,8,12-trimethyltrideca-3‘(E),7‘(E),11‘-trienyl)-2H-1-benzopyran-6-ol]. These 
compounds occur in rice bran, barley and palm oil and decrease total and low density 
lipoprotein (LDL) cholesterol levels and inhibit HMG-CoA activity in chickens and swine 
(QURESHI et al. 2001a). Additionally they are more effective antioxidants in vitro and suppress 
B16 melanoma cell proliferation more potently than α-TOH and other T3s (QURESHI et al. 
2000). Further, atherosclerotic plaque formation was reduced by the novel T3 compounds in 
C57BL/6 apolipoprotein E (ApoE)-deficient mice (QURESHI et al. 2001b). 
 
 




Figure 3: Tocopherol derivates. 
1.1.1.3 Further vitamin E-related natural products 
Marine derived tocopherols and α-tocomonoenol  
Since MDT are predominantly present in cold-water fish to enhance antioxidant protection 
of cellular lipids at low temperatures. In addition, effects on membrane viscosity are 
considered (FUJISAWA et al. 2010). Precursors of α-tocomonoenol synthesis are either α-TOH 
or α-T3 which form α-tocomonoenol by site-specific desaturation in phytoplankton or by 
partial reduction during α-TOH synthesis, respectively (GOTOH et al. 2009), in rice bran and 
palm oil. The origin of MDT in fish or marine vertebrates which can accumulate in humans 
eating fish (YAMAMOTO et al. 2001) is attributed to MDT producing photosynthetic organisms, 
such as phytoplankton (FUJISAWA et al. 2010). Both α-tocomonoenol and MDT accumulate in 
fish liver and brain as well as in human plasma and show similar biologic availability as 
vitamin E. Marine derived tocopherols are partly more potent than α-TOH (FUJISAWA et al. 
2010; YAMAMOTO et al. 2001).  
 
Plastochromanol-8  
Plastochromanol-8 (PC-8) is an γ-T3-related natural product which differs in the length of the 
side-chain from other vitamin E components; instead of three isoprene units the side-chain 
of PC-8 consists of eight (OLEJNIK et al.) (see Figure 1). It is formed out of plastoquinone-9 by 
tocopherol cyclase (MENE-SAFFRANE et al. 2010). Plastochromaol-8 occurs most abundantly in 
linseed oil (OLEJNIK et al.) and also in oils from corn seed, rape seed, soybean (SONDERGAARD & 
DAM 1967), maize and latex from Havea brasilensis (WHITTLE et al. 1965). 
 
1.1.1.4 Vitamin E derivatives 
Due to their accumulation in vivo and their better stability compared to other natural and 
non-natural vitamin E homologues mostly α-tocopheryl acetate (α-TA), but also phosphate 
(α-TP) and succinate (α-TS) (see Figure 3) are often used as 
supplements in animal and human trails, such as the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study. 
Although these molecules differ in solubility, transport, 
metabolism and cellular activity from α-TOH, it is stated that 
they may act as pro-vitamins due to their conversion to 
α-TOH by intestinal or epidermal esterases (ZINGG et al. 
2010b). Zingg et al. give two possible explanations for the 
effects of synthetic derivatives (i) by directly interacting with 
specific proteins and cellular structures or (ii) by generally 
influencing organelles and membrane properties (ZINGG et al. 
2010b). 
α-Tocopheryl phosphate, for example, is discussed to act as intra- and extracellular 
transport, absorption and storage form of α-TOH (GIANELLO et al. 2005). More likely it acts as 
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a signal molecule representing the active form of α-TOH as a cofactor or ligand for enzymes 
regulating signal transduction involved in inflammatory, antioxidative, antiatherogenic 
(LIBINAKI et al. 2010) and proliferative mechanisms (NEGIS et al. 2007; ZINGG et al. 2010a). 
α-Tocopheryl acetate in contrast is of particular importance in skin diseases (PANIN et al. 
2004) and seems to be potent only after its conversion to α-TOH (FIUME 2002). α-Tocopheryl 
succinate differs mainly from its precursor by a high selectivity for malignant cells and 
simultaneous lower toxicity to healthy cells possibly due to the inability of malign cells to 
hydrolyze esters (NEUZIL et al. 2002), which characterizes it as an important therapeutic 
agent for inhibiting cancer (DONG et al. 2008) and sepsis in vivo (CUSCHIERI et al. 2007).   
Since the knowledge about the mechanisms and modes of action of vitamin E is incomplete 
the interest for natural or synthetic vitamin E isomers, derivatives and related metabolites 
still rises. Most of these compounds have been shown to affect pathways involved in 
inflammation, oxidation and of age-related diseases such as cancer, diabetes and 
atherosclerosis to different extent. As recently described non-α-TOH structures are partly 
more potent in regulation and even targets different from α-TOH-mediated effects are 
modulated (OLEJNIK et al.; ZINGG et al. 2010b).  
 
1.1.1.5 Toxicology 
Recent animal studies on reproductive or developmental toxic effects of natural or non-
natural vitamin E components were negative but anti-mutagenic activity has been shown 
(FIUME 2002). Physiological vitamin E intake of 100 mg/d can be increased up to 300 mg/d 
without any complications (YAP et al. 2001; YU et al. 2006). Even for short-term, high-dose 
administration of vitamin E no adverse effects have been described. However, persistent 
high-dose supplementation has been shown to interfere with blood clotting and is 
associated therewith to increase risk of hemorrhagic stroke in animal studies (FIUME 2002). In 
the past TOH was considered to be a safe food additive (TOMASSI & SILANO 1986). But in the 
last years an increase of total mortality after high-dose vitamin E intake was discussed 
(MILLER 2005) (Manuscript II page 42). Excessive intake of vitamin E results in enhanced 
metabolism resulting in increased α-carboxyethylhydroxychromanol (α-CEHC) formation and 
excretion via urine and the vitamin E excretion itself via bile. This suggests that vitamin E 
needs to be eliminated somehow; possibly to avoid antioxidative suppression of essential 
reactive oxygen species (ROS) signaling pathways or interaction of vitamin E with other 











Bioavailability of vitamin E is mainly regulated via four key steps outlined here in brief: 
(i)  Intestinal absorption with bile and pancreas secretion and chylomicron synthesis 
and release,  
(ii)  Distribution via lipoproteins after lipolysis of chylomicrons in plasma, 
(iii)  Hepatic uptake and transport depending on the α-tocopherol transfer protein 
(α-TTP), and 
(iv)  Distribution and uptake in non-hepatic tissue via lipoproteins, importer and exporter 
proteins.   
 
1.1.2.1 Intestinal absorption 
It is known that vitamin E as a fat-soluble vitamin follows intestinal absorption, hepatic 
metabolism and cellular uptake processes other lipophilic and lipid molecules (RIGOTTI 2007). 
The absorption rate of vitamin E varies interindividually between 20-80% (BJØRNEBOE et al. 
1990; RIGOTTI 2007), and is thus much lower than for other fat-soluble vitamins such as 
vitamin A (BOREL et al. 2001). The reasons for individual differences in absorption rate are 
diverse. Increased administration of α-TOH (TRABER et al. 1986) and parallel intake of 
additional food ingredients decrease non-α-TOH and α-TOH absorption such as retinoic acid 
(BIERI et al. 1981), plant sterols (RICHELLE et al. 2004), eicosapentaenoic acid, chronic alcohol 
consumption (BJØRNEBOE et al. 1990), and dietary fiber (DOI et al. 1983). Apparently crucial 
for vitamin E absorption is the way how it is presented to the intestinal surface (SHILS et al.). 
Additionally the supplied form of α-TOH, as free molecule or e.g. as α-TA, a common food 
additive, is of particular importance for its bioavailability (BAKER et al. 1980; BURTON et al. 
1988). Lipids and fat-soluble compounds are processed enzymatically in the stomach by 
lipase first. Vitamin E occurs in human diet mainly as free α-TOH, therefore the importance 
of the degradation in the stomach is probably limited (BOREL et al. 2001). The need of such 
gastric degradation for stabilized forms of vitamin E such as α-TA is not known due to a lack 
of investigations (BOREL et al. 2001). The more stable α-TA, a common food additive, 
however needs further hydrolysis directly by the bile acid-dependent lipases in the pancreas 
or an intestinal mucosal esterase (BJØRNEBOE et al. 1990). Subsequent vitamin E absorption in 
the duodenum is characterized by the transfer from the emulsion fat globules to water-
soluble multi- and unilamellar vesicles and mixed micelles made of phospholipids and bile 
salts, the so-called lipid emulsification. This is the fundamental step in lipid digestion which is 
therefore the crucial step in vitamin E absorption (see Figure 4). Since the transport of 
vitamin E to enterocytes is less efficient compared to other types of lipids. This may explain 
the low vitamin E bioavailability (BOREL et al. 2001). The intestinal cellular uptake of vitamin E 
from mixed micelles follows two different pathways across enterocytes as it has been shown 
in vitro and in vivo: via (i) passive diffusion and (ii) scavenger receptor class B type 1 (SR-B1) 
(REBOUL et al. 2006). Additionally, the Niemann-Pick C1-like protein 1 (NPC1L1), an apical 




Figure 4: Digestion, transport and degradation of vitamin E. Course of vitamin E after supplementary or 
nutritional intake follows in general the way of further coexisting lipid compounds. Pancreatic and 
intestinal enzymatic digestion followed by the circulation and distribution to the liver and non-hepatic 
tissues is the same for all vitamin E isomers. Discrimination in favor of α-TOH occurs mainly in the liver by 
the α-TTP, protecting α-TOH from excessive degradation and excretion. (BJØRNEBOE et al. 1990; BOREL et al. 




membrane receptor of the small intestine (HACQUEBARD & CARPENTIER 2005), transports α-TOH 
across the enterocyte membrane (NARUSHIMA et al. 2008). Niemann-Pick C1-like protein 1 is 
further responsible for the reuptake of intact α-TOH from bile to hepatocytes and prevents 
the excessive biliary loss of α-TOH together with α-TTP, which is responsible for the storage 
of α-TOH in the liver (NARUSHIMA et al. 2008). Very important ATP-binding cassette (ABC) 
transporters are ABCG5/ABCG8 and ABCA1/ABCG1, which are responsible for steroid efflux 
into the intestinal lumen and transport into the lymph system, respectively. Vitamin E up-
regulates these transporters in rats which once shows the contribution of vitamin E on 
cholesterol absorption and secretion (ROGI et al. 2011). Finally, ABCA1 is directly involved in 
vitamin E export (LEMAIRE-EWING et al. 2010).  
Until now no intestinal absorption discrimination of RRR-α-TOH over other stereoisomers 
(KIYOSE et al. 1995) or rather γ-TOH (TRABER & KAYDEN 1989) is known. Absorption efficiency 
and integration of α-TOH and γ-TOH into chylomicrons are equal.  
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1.1.2.2 Transport of vitamin E in plasma 
The transport of vitamin E in the blood follows largely the lipoprotein metabolism. 
Chylomicrons containing vitamin E, independent from the isomers or stereoisomers, and are 
secreted into the intestinal lymph system starting in the systemic circulation. Chylomicrons 
are catabolized via lipoprotein lipase (LPL) (HACQUEBARD & CARPENTIER 2005; KIYOSE et al. 1997). 
During this lipolysis step vitamin E is either incorporated into high density lipoprotein (HDL) 
and to other circulating lipoproteins such as LDL by the phospholipid transfer protein (PLTP) 
(SHILS et al.), or to chylomicron remnants. An additional member of the lipid transfer 
proteins, the cholesteryl ester transfer protein (CETP), is discussed to take part in vitamin E 
transport and metabolism (LEMAIRE-EWING et al. 2010). Vitamin E incorporated in chylomicron 
remnants is further imported into the liver via LDL receptor-related protein (LRP) and the 
LDL receptor (LDLR) (HERZ et al. 1995; LEMAIRE-EWING et al. 2010). Until now no specific 
plasma transport proteins for α-TOH have been described (BJØRNEBOE et al. 1990; TRABER 
2013). Lipoproteins serve as carriers for lipophilic molecules, such as vitamin E, to transport 
them between lipoproteins and from lipoprotein to tissue (BJØRNEBOE et al. 1990). Under 
physiological conditions α-TOH is mostly transported via very low density lipoprotein (VLDL) 
and HDL (BJØRNEBOE et al. 1986), whereas under fasting conditions LDL take on this task. 
Although VLDL have the highest capacity to carry α-TOH, these particle represent the 
smallest fraction in vitamin E transport via lipoprotein in the circulation in the fasted state 
(BEHRENS et al. 1982). 
 
1.1.2.3 Hepatic transport 
Studies in rats have shown that α-TOH is present in the liver and plasma after one week of 
supplementation, but in adipose tissue only after two months of supplementation 
(WEISER et al. 1996). α-Tocopherol is secreted by the liver in nascent lipoproteins such as 
VLDL whereas γ-TOH is secreted to bile (TRABER & KAYDEN 1989). Hence discrimination of TOH 
isomers and stereoisomers occurs mostly in the liver via α-TTP which discriminates 
predominantly in favor of α-TOH and preferentially secretes isomers with 2R configuration 
(RRS, RSR, RSS) and RRR configuration to VLDL. α-Tocopherol from the plasma accumulates 
in adipose tissue, liver and brain (but also 2S isomers are present in these tissues) 
(KIYOSE et al. 1997; WEISER et al. 1992). The lipoproteins LDL, VLDL and HDL preferentially 
take up R-isomers instead of S-isomers, therefore the bioavailability of RRR-α-TOH is 
significantly greater than that of all/-rac-α-TA (KIYOSE et al. 1997). Traber et al. mentioned 
that lipoproteins returned RRR-α-TOH to the plasma in unaltered form, whereas all non-RRR-
α-TOH are metabolically degraded primarily followed by their excretion (GIANELLO et al. 2005; 
TRABER et al. 1990). In the liver of rats, parenchymal cells, such as Kupffer cells, store 75-90% 
of injected α-TOH which is suggested to be predominantly located in mitochondria, 
lysosomes and Golgi apparatus compared to non-parenchymal cells (BJØRNEBOE et al. 1990). 
Arita and co-workers showed that α-TOH secretion out of the liver is independent of VLDL 
assembly and secretion and suggested that oxysterol-binding proteins (ARITA et al. 1997) or 
ABCA1 (ORAM et al. 2001) are possibly involved in α-TOH secretion. Finally, only 1% of the 
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total body TOH is transported in the blood (HORWITT et al. 1972). 
 
1.1.2.4 Intercellular transport and intracellular distribution of vitamin E – 
tocopherol binding proteins 
Both SR-B1 and ABCA1 are of particular importance for the uptake and efflux within the 
vitamin E distribution pathways (LEMAIRE-EWING et al. 2010). Scavenger receptor B1 mediates 
vitamin E uptake in the intestine and in peripheral tissue whereas LDL and LRP are involved 
in uptake in the liver. Efflux of vitamin E via ABCA1 takes place in the intestine and the liver. 
Additionally, ACBA1 regulates the cellular efflux of vitamin E in macrophages and fibroblasts 
(ORAM et al. 2001). This finding reinforces the presumption of similarities between 
cholesterol and α-TOH transport. Further the multidrug resistance (MDR) P glycoprotein 
(Pgp or MDR1) has been identified to regulate α-TOH transport across the plasma membrane 
and its secretion into the bile (MUSTACICH et al. 1998).  
Next to α-TTP further intracellular α-TOH transporters, the tocopherol associated protein 
(TAP) and the tocopherol-binding protein (TBP), are known. Tocopherol associated protein 
as a member of the hydrophobic lipid-binding protein family seems to be identical with the 
supernatant protein factor (SPF) (STOCKER et al. 1999), and mediate antiproliferative effects 
in different prostate cancer cells by promoting vitamin E uptake or independently of α-TOH 
effects (CARDENAS & GHOSH 2013; NI et al. 2005), whereas TBP may be involved in intracellular 
distribution of α-TOH (HACQUEBARD & CARPENTIER 2005). Supernatant protein factor is involved 
in cholesterol synthesis, whereas TAP/SPF forms complexes with RRR-α-tocopheryl quinone, 
the oxidation product of α-TOH, but the function of SPF needs further investigation 
(SHILS et al.; STOCKER & BAUMANN 2003). Both α-TTP and TAP belong to a family of ligand 
binding proteins that have a cis-retinal binding motif sequence, the so-called CRAL_TRIO. All 
members of this family bind α-TOH but in a minor proportion compared to α-TTP, but their 
physiological relevance is unknown (SHILS et al.). Further an α-TOH binding protein of 
14.2 kDa has been detected in the liver which is characterized by similar specificity for α-TOH 
compared to α-TTP and is important for the regulation of cellular α-TOH concentration and 
intracellular α-TOH transport (DUTTA-ROY et al. 1993). As α-TTP occurs additionally in 
placenta the importance of α-TOH to prevent fetus resorption is obvious (TRABER & SIES 1996) 
and the expression of α-TTP in several other tissues suggests relevance for intra-organ traffic 
(BRIGELIUS-FLOHÉ 2009). 
 
1.1.3 Metabolism of vitamin E 
In contrast to other fat-soluble vitamins vitamin E does not accumulate in the liver to toxic 
levels (SHILS et al.), because excessive vitamin E intake leads to increased vitamin E 
metabolism. Within the group of vitamin E, α-TOH is dominant in animals and humans, as a 
result of the postulated α-TTP discrimination or rather enhanced metabolic degradation of 
the non-α-TOH isomers by cytochrome P450 enzymes and their subsequent elimination via 




Figure 5: Physiological hepatic metabolism of α-TOH. Modified 
from (BIRRINGER et al. 2002a; MUSTACICH et al. 2010) 
 
urine (ZINGG et al. 2010b). As already mentioned hepatic α-TTP preferentially promotes the 
incorporation of α-TOH in VLDL in the liver. Hosomi and co-workers estimated the relative 
affinities of α-TTP to different vitamin isomers and stereomers starting from RRR-α-TOH set 
to 100%: β-TOH 38%, α-T3 12%, SRR-α-TOH 11%, γ-TOH and trolox 9% followed by δ-TOH, 
α-TA and α-TOH quinone with 2%, (HOSOMI et al. 1997). Requirements for binding of 
vitamin E isomers and derivates to α-TTP are the three methyl groups of the chromanol ring 
system, especially at position C5, the free hydroxyl group and the phythyl side-chain 
(HOSOMI et al. 1997). Since the affinity of vitamin E isomers to α-TTP reflects the biological 
activity from rat resorption-gestations assay (LETH & SONDERGAARD 1977), the hypothesis that 
α-TTP is responsible for the discrimination of α-TOH is supported. A current study from 
Grebenstein et al. raises the presumption that the metabolism of vitamin E but not α-TTP 
discriminates mainly non-α-TOH isomers, as α-TTP protects the side-chain of vitamin E 
isomers from ω-hydroxylase-induced degradation (GREBENSTEIN et al. 2014). High levels of 
expression of α-TTP lead to higher intracellular concentrations of γ-TOH combined with a 
reduced production of γ-CEHC, which confirms the concept that α-TTP binding protects from 
degradation. As suggested by Grebenstein et al. the long-chain metabolites (LCMs) of 
vitamin E are possible ligands for 
TTP and/or other hepatic TOH 
binding proteins. Further, the 
importance of these proteins for 
LCM transfer to mitochondria 
needs to be investigated 
(GREBENSTEIN et al. 2014).  
In the liver the metabolism of 
vitamin E, mainly α-TOH, occurs in 
three cell compartments:  
microsomes, peroxisomes and 
mitochondria (Figure 5). So far it 
is not known how the metabolites 
enter the peroxisome or leave it. 
In microsomes side-chain trun-
cation is initiated by CYP4F2/3A4-
dependent ω-hydroxylation which 
is the initial step resulting in the 
formation of the alcohol derivate 
α-13’-OH (13’-(6-hydroxy-2,5,7,8,-
tetramethylchroman-2-yl)-2,6,10-
trimethyltridecanol) (PARKER et al. 
2000; SONTAG & PARKER 2002). 
Subsequent α-oxidation in 
peroxisomes forms the acid 
derivate α-13’-COOH (13’-(6-
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hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyltridecanoic acid) via the 
aldehyde metabolite processed by alcohol and aldehyde dehydrogenase activity. The hydro-
xychromanols and carboxychromanols, will be abbreviated in the presented manuscript as 
α-13’-OH and α-13’-COOH, respectively and classified as LCMs. In the peroxisomes two 
β-oxidation cycles cause the elimination of either propionyl-CoA or acetyl-CoA and formation 
of the intermediate-chain metabolites (ICM), followed by three cycles of mitochondrial 
β-oxidation. This results first in short-chain metabolites (SCM) and finally in α-CEHC, the 
catabolic end-product of TOH and T3 degradation (BIRRINGER et al. 2002a). The CEHC 
precursor carboxymethylbutylhydroxychromane (CMBHC) is the main product of T3 
metabolism in vitro which may be explained by a slower CMBHC to CEHC conversion 
compared to the previous β-oxidation steps (BIRRINGER et al. 2002a). Until now the CEHC 
isomers α-, δ- and γ-CEHC have been detected in sulfated or glucuronidated form 
(CHIKU et al. 1984; SWANSON et al. 1999) and are further excreted via urine (BRIGELIUS-FLOHÉ & 
TRABER 1999) or bile (KIYOSE et al. 2001). But these metabolites were also found in plasma 
(STAHL et al. 1999). Although vitamin E catabolism is more rapidly for T3s than TOHs and 
varies within the TOHs, the metabolic pathway is the same (BIRRINGER et al. 2002a). In 
contrast to TOHs the double bonds of T3 remains in the side chain while entering the 
β-oxidation pathway which implies the involvement of further enzymes, possibly two 
auxiliary enzymes 2,4-dienoyl-CoA reductase and 3,2-enoyl-CoA isomerase known from 
linoleic acid metabolism (BIRRINGER et al. 2002a). γ-Tocopherol is metabolized faster than 
α-TOH which can be explained partly by a higher affinity of the ω-hydroxylase to γ-TOH than 
α-TOH (SONTAG & PARKER 2002). The SCM of γ-TOH γ-CEHC is excreted via urine and bile 
(KIYOSE et al. 2001). Parallel administration of α-TOH and γ-TOH in equal amounts leads to 
increased γ-CEHC excretion via bile (6 h to 18 h) and urine (18 h to 36 h) compared to sole 
administration of γ-TOH (KIYOSE et al. 2001). The authors concluded that γ-CEHC excretion is 
gradually shifted from bile to urine and that α-TOH may affect γ-TOH metabolism 
(KIYOSE et al. 2001). Only 1-3% of the intaken RRR-α-TOH was catabolized to α-CEHC 
(SCHUELKE et al. 2000). Supplementation of α-TOH led simultaneously to increased α-TOH 
plasma levels and higher amounts of α-CEHC in urine. Hence α-CEHC can be used as a 
marker for α-TOH status in healthy humans (SCHULTZ et al. 1995). Schuelke and co-workers, 
however, suggest that α-CEHC excretion may increase only after exceeding an individual 
α-TOH threshold (30-50 µM), depending on plasma lipid concentrations (HORWITT et al. 1972; 
SCHULTZ et al. 1995); and is therefore a marker for (super)optimal α-TOH supply 
(SCHUELKE et al. 2000). Schultz et al. first identified α-CEHC as the metabolic end-product of 
α-TOH in human urine and called into question the hitherto so-called Simon metabolites. 
They suggested that the Simon metabolites are oxidative workup artifacts (SCHULTZ et al. 
1995) (see Chapter 1.1.4.1). Next to the established α-carboxyethylhydroxychromanol, 
α-CEHC glycine, α-CEHC glycine glucuronide and α-CEHC taurine have been detected in 
humans and mice by Johnson suggesting that further metabolic pathways for vitamin E may 
exist (JOHNSON et al. 2012). 
Vitamin E metabolism is not specific. Since hepatic metabolism of vitamin E follows 
xenobiotic pathways, xenobiotic transporters may act as transporters for the metabolic end-




 Figure 6: Mechanisms of classical antioxidant activity  
 under strong oxidative conditions. (BJØRNEBOE et al. 1990; 
 BRIGELIUS-FLOHÉ 2009; KONTUSH et al. 1996) 
 
product CEHC (SHILS et al.). Cometabolism of xenobiotics and vitamin E may affect 
bioavailability and mechanisms of regulation by using the same transporters and enzymes 
(JOHNSON et al. 2012), as described for γ-TOH and simvastatin (TRABER 2010). As the pregnane 
X receptor (PXR) binds vitamin E and regulates xenobiotic detoxification via CYP3A it may be 
important for vitamin E metabolism and regulation of its xenobiotic pathways (TRABER 2010). 
The second cytochrome P450 member CYP4F2, which mediates ω-hydroxylation is not 
specific for vitamin E and plays also a role in eicosanoid and vitamin K1 metabolism (TRABER 
2010), which represents the diversity and thus the complexity of vitamin E metabolism.  
 
1.1.3.1 Vitamin E deficiency and metabolic disorders 
As vitamin E is primarily stored to a large extent in adipose tissue (90%, SHILS et al.) vitamin E 
deficiency is almost unknown under physiological conditions. Symptoms of slight vitamin E 
undersupply become apparent late, usually after decades (SHILS et al.), since vitamin E can be 
mobilized from adipose tissue storages. In contrast, serious vitamin E deficiencies manifest 
in acute symptoms, such as neuropathy and myopathy, as vitamin E is essential for the 
development of the central nervous system. Next to already described dietary habits several 
hereditary disorders are known which result in inadequate vitamin E bioavailability and 
deficiency, such as malabsorption (SHILS et al.), abetalipoproteinaemia, caused by a mutation 
in the microsomal triglyceride transfer protein, as well as, the familial isolated vitamin E 
deficiency, which is also known as ataxia with isolated vitamin E deficiency (AVED) and is 
caused by various mutations concerning the α-TTP resulting in inadequate distribution of 
vitamin E in the periphery (OUAHCHI et al. 1995; SCHUELKE et al. 2000). Further Marinesco-
Sjögren syndrome and chylomicron retention disease known as Anderson disease are 
possible reasons for severe vitamin E deficiency. Both diseases are caused by a failure of 
enterocytes to assemble or deliver chylomicrons due to disturbed intestinal fat transport 
(AGUGLIA et al. 2000; GORDON 2001).  
 
1.1.4 Vitamin E – antioxidative or prooxidative capacity  
1.1.4.1 Antioxidant capacity 
Within the group of vitamin E α-TOH is 
known as the most important lipid-
soluble radical chain-breaking anti-
oxidant, mainly due to its protection 
against peroxidation of PUFA in 
phospholipids in cell membranes and 
plasma lipoproteins at least in vitro 
(Figure 6) (BRIGELIUS-FLOHÉ 2009; 
BURTON & INGOLD 1989). Higher PUFA 
intake requires a higher vitamin E 




Figure 7: Formation of Simon metabolites. Modified 
from (SCHULTZ et al. 1995) 
 
 
  Figure 8: Antioxidant activity under mild oxidative conditions (KONTUSH et al. 1996). 
 
supply to provide adequate antioxidative capacity against lipid peroxidation. Fatty acids due 
to their sterical properties tend to form radicals which can be scavenged by the free hydroxyl 
group at the chromanol ring of α-TOH. To 
recover the intact α-TOH molecule it 
reacts with a second peroxyl radical or 
tocopheroxyl radical under strong 
oxidative conditions. Additionally, 
oxidation of α-TOH in the liver forms 
α-TOH quinone and further α-TOH 
hydroquinone which is excreted to the 
bile after conjugation with glucuronic 
acid (BJØRNEBOE et al. 1990). Subsequently 
tocopheronic acid and tocopherono-
lactone arise and are excreted via the 
second possible pathway, the urine 
(BJØRNEBOE et al. 1990). These metabolic 
products first were described by Simon et 
al. in 1956, and are therefore called 
Simon metabolites. They were probably 
wrongly accepted as the catabolic end-
products of vitamin E metabolism instead of CEHC for many years (see Figure 7) 
(SCHULTZ et al. 1995). Nevertheless formation of Simon metabolites indicates that antioxidant 
reactions of α-TOH cannot be excluded completely (BRIGELIUS-FLOHÉ 2009). 
Under mild oxidative condition the tocopheroxyl radical needs coantioxidants to be 
regenerated into its intact TOH form which can be used for scavenging free radicals in a 
hydrophobic milieu (see Figure 8) (KONTUSH et al. 1996). The most important coantioxidant is 
ascorbic acid which further forms an ascorbyl radical under regeneration of α-TOH. The 
reduction to ascorbic acid transfers the radical to glutathione (GSH). The subsequent 
reduction back to GSH is enabled by nicotinamide adenine dinucleotide phosphate (NADPH) 
providing its hydrogen.   




Figure 9: Steric disturbance of phospholipids by α-T3 
(A) and α-TOH (B) in biological membranes near non-
raft domains (ATKINSON et al. 2010; SEN et al. 2007). 
 
1.1.4.2 Vitamin E acting as a prooxidant  
Next to the extensively investigated antioxidative properties of vitamin E/α-TOH 
prooxidative properties of high vitamin E doses in vitro and in vivo are discussed. High levels 
of cations such as ferrous ions in combination with α-TOH in vitro could increase production 
of hydroxyl radicals or reactive proteins bound to α-TOH at hydrophilic membrane sites 
(SCHWARTZ 1996). Even in vivo vitamin E supplementation was described repeatedly as a 
potential risk factor for increasing gastrointestinal symptoms and total mortality (MILLER 
2005), possibly induced by increased oxidative activity in plasma (PEARSON et al. 2006). Apart 
from the question if vitamin E acts as a pro- or antioxidant several studies simply showed no 
effect after supplementation whether at high or low doses (WALLERT et al. 2014). As 
investigated by Kontush and coworkers the availability of α-TOH-related coantioxidants, 
such as ascorbic acid or bilirubin, determines the behavior of α-TOH as pro- or antioxidant 
under mild oxidative conditions in human plasma or isolated LDL particles (KONTUSH et al. 
1996), whereas under a deficiency of coantioxidants α-TOH exerts its prooxidant properties. 
However, under strong antioxidative conditions α-TOH acts independently of coantioxidants. 
Increased oxidation under mild oxidative conditions may be caused a slight parallel increase 
of PUFAs and is reversible by adding physiological amounts of ascorbic acid as observed by 
Kontush (KONTUSH et al. 1996). In contrast to these results observations from other groups do 
not confirm the prooxidative effects of α-TOH in vivo (ROBERTS et al. 2007). α-Tocopherol is 
quantitatively the most important antioxidant occuring in LDL particles, next to γ-TOH, 
carotenoids and ubiquinol-10 (KONTUSH et al. 1996). Since oxidation of LDL is a key event in 
atherogenesis α-TOH may play an important role in this initial step.  
 
 
1.1.4.3 Vitamin E in biological membranes 
Vitamin E isomers are components cellular of membranes with the highest accumulation in 
liposome membranes; more precisely 
vitamin E is located in the phospholipid 
bilayer in different conformations 
depending on the isomer class (Figure 9). 
In contrast to TOHs containing three chiral 
centers T3s have only one which explains 
the different conformations, position in 
and penetration of phospholipid bilayers 
of cellular membranes (Figure 9) 
(ATKINSON et al. 2010; SEN et al. 2007; 
WONG & RADHAKRISHNAN 2012). Crucial for 
incorporation into membranes are the 
methylation and the saturation patterns 
of vitamin E isomers which determine 
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their lipophilicity (BRIGELIUS-FLOHÉ 2009). In general, α-TOH occurs in membranes 1:100-1000 
compared to phospholipids (BRIGELIUS-FLOHÉ 2009).  
The structural role of α-TOH in lipid domains of all membranes may be analogous to that of 
cholesterol in lipid rafts (ATKINSON et al. 2010; MARQUARDT et al. 2013). But discrepancies 
occur about the precise localization of α-TOH within the phospholipid bilayer. α-Tocopherol 
can segregate in lipid rafts (ROYER et al. 2009), but its localization in PUFA-rich domains 
seems to be more likely (ATKINSON et al. 2010). This so-called lipid raft hypothesis can be one 
possible regulatory pathway of α-TOH in signal transduction, possibly by modifying protein-
lipid and protein-protein interactions, because most of the enzymes known to be regulated 
by α-TOH are associated with lipid rafts (LEMAIRE-EWING et al. 2010).  
Jeffrey Atkinson mentioned that the membrane saturation status is apparently responsible 
for the depth the hydroxyl group of α-TOH penetrates in the membrane (ATKINSON et al. 
2010) which affects its antioxidative abilities. This hypothesis is questioned by findings of 
Marquardt et al. who did not find an association between hydrocarbon saturation and 
α-TOH location (MARQUARDT et al. 2013). Further different hypotheses have been proposed 
on how deep α-TOH penetrates in the membrane (AFRI et al. 2004). In general the chromanol 
ring is accepted as the outer part of the vertically arranged α-TOH either located deep in the 
phospholipid bilayer or rather at the hydrophobic-hydrophilic interface. The localization of 
α-TOH with the C5 and C7 methyl groups near the interface makes it possible to inhibit lipid 
oxidation more efficiently (AFRI et al. 2004; MARQUARDT et al. 2013) and to interact with 
ascorbic acid for subsequent regeneration of α-TOH after radical reaction. The antioxidative 
capacity of α-TOH does not prevent radical formation in the cytosol or even initial oxidation 
of fatty acyl chains but it probably intercepts free radicals near the lipid/water interface and 
terminates lipid peroxide chain reactions deep in the membrane (MARQUARDT et al. 2013). 
Diplock and coworkers proposed that the antioxidative capacity of α-TOH on PUFAs is 
explained by the formation of complexes of α-TOH and non-raft PUFA chains of membrane 
phospholipids, whereas pockets are formed by the double bonds of the PUFA and the 
methyl groups at positions C4 and C8 of the isoprenoid side-chain of α-TOH (DIPLOCK & LUCY 
1973).  
Furthermore, to protect lipid membrane components against lipid peroxidation, α-TOH 
stabilizes membranes as a result of decreasing its fluidity possibly by forming complexes with 
destabilizing lipid compounds, such as free fatty acids or lysophospholipids within the 
membrane (BRIGELIUS-FLOHÉ 2009; LEMAIRE-EWING et al. 2010). α-Tocopherol may be involved 
in signaling and membrane processes, such as fusion, vesicular transport, and transmitter 




1.1.5 Non-antioxidative properties of vitamin E  
Since vitamin E scavenges ROS and nitrogen species function of vitamin E was believed to be 
limited to its antioxidant properties for several years (ZINGG et al. 2010a). Properties 
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independent of the antioxidation were first suggested in the early fifties but not pursued for 
further decades (ABE et al. 2007; AZZI 2007). Research of Angelo Azzi and colleagues over 
years brought forth several working hypotheses regarding non-antioxidative properties of 
vitamin E or rather α-TOH. Thereby the focus of vitamin E research changed towards the 
modulation of gene regulation and enzyme activities, signaling cascades within uptake, 
transport, degradation, metabolism and excretion of TOH, lipoprotein uptake and 
inflammation, to name only a few (BRIGELIUS-FLOHÉ 2009). These non-antioxidative properties 
control also severally events in atherosclerosis, for example inhibition of smooth muscle cell 
(SMC) proliferation, preservation of endothelial integrity, inhibition of monocyte-endothelial 
adhesion, inhibition of monocyte ROS and cytokine release, and inhibition of platelet 
adhesion and aggregation (AZZI 2007). The initial finding in this field was the inhibition of PKC 
activity and vascular SMC growth by α-TOH (AZZI et al. 2002). Following observations 
demonstrated the inhibition of PKC in various cell types with consequent inhibition of 
platelet aggregation, nitric oxide production in endothelial cells (EC) and superoxide 
production in neutrophils and macrophages (AZZI et al. 2002). In addition, scavenger 
receptors (SR), adhesion molecules and collagenase seem to be under the non-antioxidant 
control of α-TOH (AZZI et al. 2002). In summary, the spectrum of action includes reactions on 
the level of cellular processes and transcriptional regulation (AZZI et al. 2002). A detailed 
overview of non-antioxidative regulation by α-TOH presented in Manuscript II (see page 42).  
Antioxidative properties were confirmed in vitro but validation mostly failed in vivo when 
accepted markers of oxidative damage were considered (BRIGELIUS-FLOHÉ 2009). Non-α-TOH 
isomers known for their smaller antioxidative capacity show comparable cellular functions 
which suggest that molecular structures are responsible for providing non-antioxidant 
functions (AZZI 2007). Finally the identification of a key regulator by which α-TOH influences 
gene activity is still missing (BRIGELIUS-FLOHÉ 2009). 
 
1.1.6 Prevention of age-related diseases by vitamin E 
In the USA about 11% of the population consumes vitamin E supplements daily 
(PEARSON et al. 2006). Also in Germany vitamin E supplementation is widespread although 
the effects of vitamin E are only incompletely understood. In recent years the discussion 
whether vitamin E increases all-cause mortality was sparked by Miller (MILLER 2005), but the 
question has not been resolved yet (TRABER 2007). The Heart Outcomes Prevention 
Evaluation Study Extension (HOPE-TOO) trial reported a higher risk of heart failure and 
hospitalization due to heart failure in cardiovascular disease patients after vitamin E 
supplementation. But until today evidence for adverse side effects of vitamin E supplements 
up to 1000 mg (1600 IU) in healthy people are missing (HATHCOCK et al. 2005). On the other 
hand the benefit of vitamin E or rather α-TOH on age-related diseases, such as 
cardiovascular disease (CVD), cancer or Alzheimer disease, is still not proven (FORTMANN et al. 
2013). Several antitumor effects of vitamin E have been shown in vitro and in animal studies 
but failed to be reproduced in humans (WADA 2012). In contrast to TOH the T3 are a further 
option for intervention in cancer studies but large-scale clinical trials are still missing (WADA 
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2012). In addition to unconfirmed anticancer effects, possibly cancer promoting effects have 
been shown in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) which focused 
on the impact of vitamin E supplementation and the development of prostate cancer 
(KLEIN & THOMPSON 2012). Similar observations were made for CVD and vitamin E 
supplementation (DUTTA & DUTTA 2003). As discussed in several reviews the promising in vitro 
reports on vitamin E acting as an antioxidant failed to be reproduced in vivo (CORDERO et al. 
2010). As evidence supporting the hypothesis that α-TOH does not act as an antioxidant in 
human atherosclerotic plaques, coexistence of oxidized lipids and α-TOH has been suggested 
(SUARNA et al. 1995). For further details regarding benefits of vitamin E supplementation on 
CVD see also Manuscript II within this thesis (page 42). Similar observations have been made 
also for other antioxidants.      
Alzheimer disease is discussed to be at least partly a vascular disease. Since oxidative 
processes are leading cause of Alzheimer disease, treatment with antioxidants such as 
vitamin E is possibly relevant in disease prevention. Except for one clinical trial (SANO et al. 
1997), no clinical benefit of vitamin E supplementation has been described, although 
decreased lipid peroxidation in plasma and cerebrospinal fluid has been found (ARLT et al. 
2012). As known a positive correlation of vitamin E supplementation and CVD in intervention 
trials failed for several reasons. Comparable observations have been described for vitamin E 
treatment and prevention of Alzheimer disease (BREWER 2010). Therefore Farina et al. 
concluded that vitamin E supplementation for protecting against Alzheimer disease is 
questionable (FARINA et al. 2012). Further investigations are needed to clarify the mode of 
action of vitamin E in preventing Alzheimer disease with special focus on individual changes 
in redox potential (BREWER 2010; LLORET et al. 2009). 
Angelo Azzi provided further data on in vitro antioxidants, e.g. which do not have 
comparable effects in vivo and concluded that chemically tested antioxidants do not have 
necessarily antioxidant properties in vivo (AZZI 2007). 
 
 
1.1.7 Physiological metabolites of α-TOH 
1.1.7.1 Detection of physiological metabolites 
Vitamin E metabolism has been studied intensively since the 1990`s but is not yet complete. 
The current knowledge on vitamin E metabolism is summarized in section 1.1.3. Starting in 
hepatic cell culture systems first analyses regarding formation of different TOH and T3 
metabolites were performed (BIRRINGER et al. 2002a; SONTAG & PARKER 2002). For many years 
detection of the catabolic end-product of vitamin E metabolism CEHC, mainly γ-CEHC and 
α-CEHC, has been known. These so-called SCM are commonly found in rodent and human 
urine (CHO et al. 2009; LEBOLD et al. 2012) as well as human plasma (HENSLEY et al. 2004). Zhao 
and coworkers detected successfully different TOH and T3 metabolites in mice (feces, urine, 
liver and serum) and in human (feces, urine and serum) samples (ZHAO et al. 2010). They 
were able to detect unconjugated SCMs, intermediate metabolites and LCMs of α-, γ-, δ-TOH 
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and their precursor, TOHs and T3s themselves, in fecal samples of mixed-TOH supplemented 
mice and TOH supplemented humans. Since α-TOH is primarily taken up via α-TTP and thus 
escapes the degradation, as described previously, the amounts of non-α-TOH metabolites 
are increased compared to α-TOH metabolites (ZHAO et al. 2010). In murine and human urine 
samples SCM of TOH and T3 have been detected only as glucuronide conjugates. In serum 
and liver samples TOH itself and its metabolites accumulate under supplementation 
(ZHAO et al. 2010). The intermediate-chain metabolites, usually detected by GC/MS, are 
short-lived intermediates and therefore no significant amounts are detected in liquids and 
tissues (BIRRINGER 2010). Long-chain metabolites, the first metabolic products arising during 
the catabolism of vitamin E, α-, γ- and δ-13’-OH as well as corresponding 13’-COOH 
metabolites and subsequent metabolites (11’ and 9’) have been detected as conjugated or 
unconjugated structures in cell culture media (JIANG et al. 2007; SONTAG & PARKER 2002; 
YOU et al. 2005), human liver cells (BIRRINGER et al. 2010; MUSTACICH et al. 2010), rat plasma 
and liver (FREISER & JIANG 2009a; JIANG et al. 2007) and rather human liver (SONTAG & PARKER 
2002) using GC/MS, HPLC with fluorescence detection, mass spectrometry or rather ion-
coupled plasma mass spectrometry, which are suitable for detection of conjugated 
metabolites (BIRRINGER 2010).  
 
1.1.7.2 Non-antioxidative effects of vitamin E metabolites 
Many transcription regulatory properties have been described for α-TOH and for its 
structure-related isomers and derivatives. Investigation of non-α-TOH compounds showed 
similar or partly more potent properties compared to α-TOH (GALLI et al. 2004a; GALLI et al. 
2004b; SEN et al. 2007). Therefore structurally related compounds are in the focus of current 
research projects.  
Next to their antioxidative capacity (VARGA et al. 2008) SCMs are known to mediate 
antiproliferative effects in PC-3 prostate cancer cells (CONTE et al. 2004; GALLI et al. 2004b), 
act antineoplastically and natriuretically (WECHTER et al. 1996), reduce the inflammatory 
response in stimulated rat aortic endothelial cells (RAECs) and mouse microglial cultures 
(EOC-20) through inhibiting prostaglandin (PG) E2 and nitric oxide production and release 
(GRAMMAS et al. 2004). Comparable antiinflammatory effects were shown in rats (JIANG & 
AMES 2003). Jiang and coworkers showed the inhibition of cyclooxygenase activity in murine 
RAW264.7 macrophages and A549 human epithelial cells (JIANG et al. 2000).  
Improved analytical procedures allowed the detection of further intermediate metabolites 
(FREISER & JIANG 2009b; JOHNSON et al. 2012). Until now each physiological metabolite arising 
from hepatic catabolism of vitamin E was found in fluids and/or tissue of humans or animals. 
Nevertheless the physiological and pathophysiological role and the biological activity of the 
metabolites with an emphasis on the LCMs are rare because they were not available as pure 
compounds until recently so that now standards were available. Until know the LCMs have 
been identified only in human liver cells, human alveolar basal epithelial cell culture medium 
and rat plasma (BIRRINGER et al. 2001; BIRRINGER 2010; FREISER & JIANG 2009a; JIANG et al. 2007). 
Whether the LCMs are present in serum and how they are transported in serum is not 




Figure 10: Synthesis of α- and δ-LCM starting from garcinoic acid 
modification. (BIRRINGER et al. 2010) 
 
known. Although the 
chemical synthesis of these 
LCMs starting from a δ-T3-
derivate (trans-13’carboxy-
S-tocotrienol-S’trans-
tocotrienoloic acid 2R, 3’E, 
7’E, 11’E-13’-carboxy-S-
tocotrienol MAZZINI et al. 
2009), the so-called 
Garcinoic acid (Figure 10), 
the main ingredient of an 
African bitter nut, has been 
known for some years, first 
data were published only six years ago. Latest data on the biological activity of the LCM are 




Atherosclerosis and its complications such as stroke and myocardial infarction are next to 
cancer the leading cause of death in Western industrialized societies and are considered as 
an age-related lifestyle disease. As reviewed by Oliveira and colleagues atherosclerosis starts 
in childhood or even in fetal development and manifests in the last third or fourth of life-
time (OLIVEIRA et al. 2010). Since atherosclerotic events have been increasing over the last 
decades it seems to be a problem of the modern affluent society characterized by an 
oversupply of food and an unhealthy lifestyle in general. However, there are hints for 
atherosclerosis being present in ancient times diagnosed as atherosclerotic changes in 
vessels of mummies (RÜHLI et al. 2004; THOMPSON et al. 2013). Based on these findings 
lifestyle and nutrition (DAVID et al. 2010) and genetic predispositions are main risk factors of 
atherosclerosis next to age (OLIVEIRA et al. 2010). 
 
1.2.1 Atherogenesis 
Atherosclerosis is a progressive inflammatory disease of middle and large-sized arteries 
characterized by extensive morphological changes of the vascular wall. The pathogenesis of 
atherosclerosis is initiated by endogenous and exogenous noxes accompanied by endothelial 
dysfunctions which lead to intimal thickening caused by T-cell and monocyte recruitment as 
well as their migration into the subintimal space. In brief subsequent progressive events in 
atherosclerosis are macrophage differentiation, immigration of SMCs, lipid accumulation in 
macrophages and proliferation of lipid-loaded macrophages, deposition of cholesterol and 
fibrotic material, foam cell formation, fatty streak formation, elasticity loss and vascular 
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lumen reduction with parallel widening of the arterial diameter (WALLERT et al. 2014). Taken 
together these events progress over decades resulting in the formation of a necrotic lipid 
core with a fibrotic cap which is destabilized by proteases released by macrophages. Finally 
plaque rupture followed by thrombus formation may take place. Subsequently two possible 
pathways are conceivable: the thrombus (i) flows downstream with the blood to small 
volume arteries and causes vascular occlusions, or (ii) it remains at the plaque site where it 
may also occlude the artery. Incorporation of the thrombus at the plaque site leads to the 
formation of the so-called complicated plaque (WALLERT et al. 2014). Risk factors and the 
initiation and propagation of atherosclerosis are described in more detail in Manuscript II 
(see page 42). 
 
1.2.2 Macrophages 
In inflammatory and lipid metabolism associated diseases such as atherosclerosis 
macrophages, the phagocytic cells of the immune system, play a pivotal role. In brief, they 
control atheroma development by releasing cytokines, ROS, and proteases resulting in 
weakening and destabilization of the fibrous cap (LIBBY 2002). Additionally macrophages 
accumulate large amounts of cholesterol esters (GOLDSTEIN et al. 1979a) and triglycerides and 
mobilize cholesterol for reverse cholesterol transport (GHOSH et al. 2010). Since excessive 
lipid accumulation leads to foam cell formation, macrophages contribute actively to 
atherosclerosis. In parallel macrophages release signaling molecules such as chemotactic 
mediators resulting in recruitment of other immune cells as well as SMCs (LIBBY 2002).  
Functional activation of macrophages as a result of the immune response to microbial 
components such as lipopolysaccharides (LPS) modifies their repertoire of pattern-
recognition receptors and this is called macrophages polarization (BISWAS & MANTOVANI 
2010). For years the concept of polarization has distinguished macrophages into two 
extreme activation states named classical (M1) or alternative (M2a, b, c) activation with 
distinct characteristics which can be switched upon appropriate stimuli (BISWAS & MANTOVANI 
2010; CHINETTI-GBAGUIDI & STAELS 2011; HOEKSEMA et al. 2012). Classically polarized 
macrophages (M1) are distinguished from M2 by the induction of inflammatory response 
genes (XUE et al. 2014) and transcription factors such as signal transducers and activators of 
transcription (STAT) family type 1, nuclear factor κ-light-chain-enhancer of activated B cells 
(NFκB) p65 subunit, peroxisome proliferator-activated receptor (PPAR) γ and liver X receptor 
(LXR) α (HOEKSEMA et al. 2012) as well as induction phagocytic activity and a distinct cytokine 
and chemokine profile (BISWAS & MANTOVANI 2010). Macrophage subtypes can switch 
between polarization status M1 and the different M2 states depending on the exogenous 
stimuli (CHINETTI-GBAGUIDI et al. 2011; HOEKSEMA et al. 2012). To what extent monocyte 
subtypes influence macrophage polarization is questionable. In comparison classically 
activated macrophages can be characterized as proinflammatory whereas alternatively 
activated macrophages mainly mediate antiinflammatory events and contribute to plaque 
stability, tissue remodeling and repair (CHINETTI-GBAGUIDI & STAELS 2011; FEIG et al. 2011). 
Subsequently the main functional classification of macrophages into classically activated 
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macrophages, wound-healing and regulatory macrophages was extended by intermediate 
forms with shared characteristics such as tumor-associated macrophages (MOSSER & EDWARDS 
2008). In continuation this spectrum model was promoted by Xue et al. who described at 
least nine distinct macrophage activation programs under inflammatory conditions which 
supports the notion of macrophages as a very heterogeneous cell population (CHINETTI-
GBAGUIDI & STAELS 2011; XUE et al. 2014). Macrophages differing in activation status show a 
stimulation-related gene expression signature represented in differences in cell surface 
markers and patterns of involved transcription factors (XUE et al. 2014). 
The orchestration of macrophage function plays a pivotal role in different physiological but 
in particular pathological conditions such as the development and progression of 
atherosclerotic plaques (BISWAS & MANTOVANI 2010; CHINETTI-GBAGUIDI & STAELS 2011). The 
induction of M2 associated gene expression goes along with atherosclerotic plaque 
development whereas M1-related markers are increased in very early lesions (CHINETTI-
GBAGUIDI & STAELS 2011). A macrophage phenotype distinct from M1 and M2 activation status 
namely Mox caused by oxidized phospholipids exists in atherosclerotic lesion of mice and 
man represents about 30% of all macrophages (CHINETTI-GBAGUIDI & STAELS 2011). M1 
macrophages are present in human carotid atherosclerotic lesions, whereas M2 
macrophages prevail in the shoulder region as well as in the periphery of the plaque 
(CHINETTI-GBAGUIDI et al. 2011; CHINETTI-GBAGUIDI & STAELS 2011). Macrophages may contain 
different kind of cytosolic lipid droplets depending on their activation: either many but small 
(M2) or fewer but bigger (M1) lipid droplets (CHINETTI-GBAGUIDI et al. 2011). 
 
1.2.3 Macrophage foam cell formation 
Dysbalanced lipid homeostasis as a combination of excessive lipid uptake and decreased 
export of lipids results in the formation of foam cells which is a hallmark of atherosclerosis 
(Figure 11). Macrophage lipid uptake mechanisms involved several surface-associated 
receptors, such as SR and lipoprotein receptors, both mediating lipid uptake and 
phagocytosis. Scavenger receptors, such as the cluster of differentiation (CD) 68 and the 
lectin-like oxidized low density lipoprotein receptor 1, contribute to the uptake of modified 
LDL via phagocytosis (SCHRIJVERS et al. 2007). The LDLR mainly binds native LDL (nLDL). Since 
the incorporated nLDL blocks its own further uptake via the LDLR, nLDL-derived cholesterol 
does not contribute significantly to foam cell formation of macrophages. Additionally, LDLR 
mediates the endocytosis of so-called minimally oxidized LDL (mmLDL) formed by 12/15-
lipoxygenases (LOX) (TSIMIKAS & MILLER 2011). However, the modification of LDL by 
myeloperoxidase (MPO) transforms it into an SR-A ligand (WANG et al. 2007). Low density 
lipoprotein receptor-related protein (LRP) 1 initiates cholesteryl ester (CE) exchange 
between LDL and the cell resulting in 12/15LOX-mediated oxygenation of CE and contributes 
further to the efflux of oxidized cholesterol back to the LDL particle (TSIMIKAS & MILLER 2011). 
The contribution of these different modified LDL particles and their receptors to foam cell 
formation is probably less significant than that of oxidized LDL (oxLDL) and their receptor 
CD36. Within the scavenger receptor family, CD36 plays a pivotal role in foam cell formation 




Figure 11: Foam cell formation. Lipid accumulation in macrophages is caused by a dysbalance between 
import and export of cholesterol. Enhanced cholesterol import, particularly LDL, can be caused by 
endothelial dysfunction which causes deposition of cholesterol-rich LDL within the arterial walls. Following 
these LDL particles are modified, predominantly oxidation by enzymes or radicals occurs. This plays a key 
role in atherogenesis. The uptake of modified LDL via different types of scavenger receptors is not 
feedback-regulated in contrast to the uptake of native LDL uptake via LDLR. Important receptors regulating 
the import of modified LDL are CD36 and SR-A which mainly bind oxLDL but also MPO-modified LDL. 
Additionally oxLDL can be taken up by phagocytosis. Since the lipid export mechanisms fail to balance the 
enhanced cholesterol uptake, overwhelming lipid droplet formation is observed. This results in lipid loaded 
macrophages which (A) proliferate and (B) form foam cells, a hallmark of atherosclerosis. (GHOSH et al. 
2010; ROBBINS et al. 2013; TSIMIKAS & MILLER 2011)  
by binding and initiation of uptake of oxLDL efficiently to a large extent (COLLOT-TEIXEIRA et al. 
2007). The oxidation of LDL occurs in vivo primarily through ferrous ions (Fe2+). Contrary to 
the uptake of nLDL the uptake of oxLDL is not subjected to negative feedback regulation 
which results in uncontrolled oxLDL uptake by macrophages. Subsequently starting from the 
Golgi apparatus lipid droplets containing CE, phospholipids, free cholesterol (FC) and 
triglycerides are formed (TSIMIKAS & MILLER 2011). Cholesteryl ester as the main component 
of LDL and oxLDL are hydrolyzed in late endosomes/lysosomes by the cholesteryl ester 
hydrolase (CEH) to FC (GHOSH et al. 2010), this is called cholesterol ester cycle (BROWN et al. 
1980). Free cholesterol is again transported back to the endoplasmic reticulum where it is 
re-esterified by the acetyl CoA acetyl transferase (ACAT) 1 and stored in lipid droplets. Since 
only FC is cytotoxic for the cells the CE are less harmful. However only FC can be transported 
by ABCA1 and G1 and therefore esterification inhibits FC export (BUHMAN et al. 2000; 




Figure 12: (A) Lipoprotein and (B) lipopolysaccharide mediated inflammatory pathways. Inflammation 
caused by both modified LDL and LPS induces pro-inflammatory pathways contribute to the propagation of 
inflammatory diseases such as atherosclerosis. Important receptors are scavenger receptors and Toll-like 
receptors which further enhance the inflammatory response by regulating signal transduction as well as 
production and secretion of cytokines and chemokines. (FITZGERALD et al. 2010; HANSSON & HERMANSSON 
2011; TSIMIKAS & MILLER 2011) 
 
PRAMFALK et al. 2012). Based on their involvement in cholesterol export the HDL receptors, 
ABCA1 and probably SR-B1, are classified as antiatherogenic (FITZGERALD et al. 2010). 
 
1.2.4 Inflammation 
Inflammation is an important part of many immune response-related diseases, such as 
rheumatoid arthritis, psoriasis and systemic lupus erythematosus, and is further assigned as 
a key risk factor for atherosclerosis, especially if chronic inflammatory diseases pre-exist 
(HANSSON & HERMANSSON 2011). Fundamental processes taking place during inflammation in 
macrophages are cytoskeletal rearrangement, macropinocytosis, increased ROS 
regeneration, reduced phagocytic capacity towards apoptotic cells, expression of 
proinflammatory genes, and the release of chemokines and cytokines, involvement of 
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transcription factors, such as NFκB, activator protein (AP) 1, interferon regulatory factor (IRF) 
3, LXR-α/β and PPARγ (TSIMIKAS & MILLER 2011) (Figure 12). Inflammatory activation of 
macrophages by both bacterial components and excessive lipid uptake is known. Modified 
lipoproteins are initiators of inflammation and cause directly and independently lipid 
accumulation. As described above native LDL is taken up by the LDLR. Additionally the LDLR 
binds mmLDL which subsequently modulate NFκB signaling, resulting in nitric oxide synthase 
(NOS) and NADPH oxidase (NOX) regulation and proinflammatory cytokine release such as  
interleukin (IL)-1β, IL-6 and RANTES (regulated on activation, normal T cell expressed and 
secreted) (TSIMIKAS & MILLER 2011). Low density lipoprotein is further a ligand of LRP-1, which 
directly regulates inflammatory signaling, and cytokine secretion (MAY 2013). Furthermore, 
mmLDL can be recognized by Toll-like receptor (TLR) 4 but with lower priority compared to 
LPS, the major ligand for TLR4 (TSIMIKAS & MILLER 2011). In general TLR2, TLR4 and TLR6 are 
key receptors regulating the inflammatory response of macrophages. Next to mmLDL MPO-
modified LDL can be phagocytized by macrophages via scavenger receptors CD36 and SR-A 
(TSIMIKAS & MILLER 2011). Oxidized LDL, known to contribute to the formation of foam cells, 
plays also an important role in the inflammatory response. Initial uptake of oxLDL by CD36 
mediates dimerization of CD36 with TLR4 and TLR6 thus activating tyrosine kinase Lyn. This 
ultimately leads to interference with NFκB signaling by myeloid differentiation primary 
response gene (MyD) 88 and TIR-domain-containing adapter-inducing interferon-β (TRIF). 
This finally causes the release of ROS, chemokines and cytokines (TSIMIKAS & MILLER 2011). 
The most important receptor for reverse cholesterol transport via HDL, SR-B1, can suppress 
LPS-induced cytokine secretion in macrophages through inhibition of TLR4-mediated NFκB 
activation (GUO et al. 2009). 
Regulation of lipid homeostasis requires balanced import via CD36, SR-A, SR-B1 and export 
mechanisms via ABCA1/G1. Increased capacity of receptors modulating cholesterol efflux 
through the reverse cholesterol transport pathway such as ABCA1 and ABCG1 decrease 
cholesterol levels within macrophages. Therefore ABCA1 and ABCG1 were assumed as anti-
inflammatory receptors playing a pivotal role in the inflammatory response (FITZGERALD et al. 
2010). Whether the antiinflammatory properties are a consequence of their lipid transport 
activity or direct interaction with STAT3 and Janus kinase (JAK) 2 is not known. Possibly the 
ABCA1 with apoA-1 interaction suppresses secretion of inflammatory cytokines in response 
to LPS stimulation or acts directly as an antiinflammatory receptor by stimulating the 
JAK2/STAT3 pathway, known as a repressor of inflammatory cytokine production (TANG et al. 
2009). Additionally, further transcription factors, namely PPARγ and LXRα/β, were described 
to repress transcriptional activation of inflammatory response genes such as inducible NOS 
(iNOS) (JOSEPH et al. 2003; PASCUAL et al. 2005). 
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2 Aim of the Study 
Apart from essential macronutrients balanced vitamin and mineral supply is a key issue in 
the current discussion about a healthy diet. In the case of vitamin and mineral intake many 
people believe that the more is the better (DWYER et al. 2014). Vitamin and mineral 
supplementation as well as enrichment in food increased over last decades (DWYER et al. 
2014). Vitamin E, especially α-tocopherol (α-TOH), is the most important lipid antioxidant 
which is widely used to prevent age-associated diseases, such as cardiovascular diseases 
(CVD), including atherosclerosis (BIRRINGER 2010). Despite increasing knowledge about 
human vitamin E metabolism little is known to justify its widespread use. Since meta-
analyses revealed even harmful effects of high vitamin E doses and a lack of protection 
against cardiovascular events, a profound understanding of vitamin E metabolism is 
mandatory (MILLER 2005; WALLERT et al. 2013 // 2014). 
The term vitamin E describes a group of isomers of which α-TOH is assigned as the most 
important vitamer. In regard to preventing cardiovascular complications studies have 
revealed controversial results and failed to demonstrate clear invers correlations or positive 
effects of vitamin E supplementation (WALLERT et al. 2014). One possible explanation for the 
different outcomes of human intervention studies could be that individual differences in 
vitamin E metabolism exist. Therefore the importance of metabolic differences in vitamin E 
metabolism needs to be clarified further.  
A complete knowledge about the metabolism of vitamin E with respect to the physiological 
properties of the metabolites α-13‘-OH and α-13‘-COOH formed from α-TOH is a 
prerequisite for future evaluations about antiatherogenic properties of vitamin E. Therefore 
the aim of this thesis was to contribute to a better understanding of the molecular modes of 
actions of the long-chain metabolites of α-TOH (α-LCM). In particular this thesis will focus on 
the detection of the α-LCMs in serum and on investigations of their regulatory features. 
Since several vitamin E metabolites have been detected in human serum and tissues except 
the α-LCMs α-13‘-OH and α-13‘-COOH (BIRRINGER 2010), successful detection of these 
metabolites will provide first evidence for a physiological relevance and will be the basis for 
further investigations. Thereby it is necessary to develop and optimize suitable analytical 
protocols including sample preparation. Analytical techniques such as HPLC, GC/MS and 
LC/MS will be tested for the detection of the LCMs. 
Since macrophages are of particular importance in atherogenesis the impact of the α-LCMs 
on human and murine macrophages will be investigated using different types of cell models. 
Macrophage foam cell formation is a key event in atherosclerosis which was reported to be 
influenced by α-TOH. Thus the effects of the LCMs on macrophage foam cell formation will 
be investigated.  
Next to foam cell formation inflammation plays a pivotal role in atherogenesis. Since murine 
macrophages are an established model for investigating the inflammatory response LPS-
activated murine RAW264.7 cells will be used for investigating the antiinflammatory 
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properties of the LCMs. 
Overall this thesis intends to elucidate the impact of the α-LCMs on atherogenic processes 
and macrophage activation, particularly in comparison to the parent compound α-TOH. 
Distinct regulatory capacity of the metabolites in combination with individual differences in 
α-TOH metabolism and transport may provide adequate explanations for contradictory 
results obtained from studies of α-TOH supplementation. This information will be a vital 
contribution for an accurate assessment of the contribution and molecular modes of action 
of vitamin E for the prevention of cardiovascular complications.  
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3 Manuscript overview 
Manuscript I:  
 
Long-chain metabolites of α-tocopherol occur in human serum and inhibit 
macrophage foam cell formation in vitro. 
 
Wallert M, Mosig S, Rennert K, Funke H, Ristow M, Pellegrino RM, Cruciani G,  
Galli F, Lorkowski S, Birringer M 
 
Free Radical Biology and Medicine (2014); 68C:43-51 
  
DOI: 10.1016/j.freeradbiomed.2013.11.009  
Date of acceptance: 13th November 2013 
 
Personal contribution to the publication:  
Maria Wallert: Performance of RT-qPCR, flow cytometry and lipoprotein as 
well as microbead uptake experiments, writing of the 
manuscript, analysis of data; optimization of uptake 
experiments  
Total contribution: 80% 
Sandy Mosig: Training of methods and supervision of flow cytometry studies, 
statistical calculations of flow cytometry experiments 
Knut Rennert: Training of methods and supervision of flow cytometry studies, 
preparation of lipoproteins, set-up of uptake experiments 
Harald Funke:   Writing and proofreading of manuscript, taking blood samples 
Michael Ristow:  Writing and proofreading of manuscript 
Roberto Maria Pellegrino:   Performance of LC/MS-QTOF experiments, analysis of data, 
establishment of protocol for metabolite analysis 
Gabriele Cruciani:   Proofreading of manuscript, analysis of LC/MS-QTOF data 
Francesco Galli: Design of serum analysis experiments, training of methods and 
supervision of analytical studies, analysis of LC/MS-QTOF data 
Stefan Lorkowski: Designed the study, analyzed the data, evaluated the results, 
proof-read the manuscript 
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Marc Birringer: Designed the study, analyzed the data, evaluated the results, 
proof-read the manuscript 
 
Key messages of Manuscript I: 
We detected α-13’-COOH for the first time in human serum by using LC/MS-QTOF. Thus 
these findings provided evidence for systemic bioavailability of this hepatic long-chain 
metabolite of α-TOH. Our study reports the relevance of long-chain metabolites, 
α-13’-COOH and its precursor α-13’-OH, on foam cell formation, a hallmark of 
atherosclerosis. The major scavenger receptor for the uptake of oxLDL, CD36, is increased by 
α-13’-COOH and α-13’-OH in contrast to α-TOH, although the uptake of oxLDL and lipid 
accumulation in presence of α-13’-COOH and α-13’-OH is decreased. This discrepancy may 
be explained by decreased phagocytic activity observed in this study. In summary we assume 
that the long-chain metabolites of α-TOH represent a new class of regulatory metabolites, 
which act more potently in the regulation of molecular pathways partly distinct from their 
precursor α-TOH.  
 
 
MANUSCRIPT OVERVIEW  | 29 
 
 
Manuscript II:  
 
Regulatory metabolites of vitamin E and their putative relevance  
for atherogenesis.  
 
Wallert M, Schmölz L, Galli F, Birringer M, Lorkowski S 
 
Redox Biology (2014); 2:495-503 
DOI: 10.1016/j.redox.2014.02.002 
Date of acceptance: 11th February 2014 
 
Personal contribution to the publication:  
Maria Wallert: Writing of the manuscript, collection and evaluation of data, 
concept development  
Total contribution: 40% 
Lisa Schmölz: Writing of manuscript, collection and evaluation of data, 
concept development 
Francesco Galli: Proofreading of the manuscript 
Marc Birringer: Writing and proofreading of the manuscript, concept 
development 
Stefan Lorkowski: Writing and proofreading of the manuscript, concept 
development 
 
Key messages of Manuscript II: 
Vitamin E, a group of different isomers of with α-TOH is assigned as the most active vitamer, 
is likely the most important antioxidant in human diet. Beside antioxidative capacity α-TOH 
exhibits antiinflammatory activity in vitro. Despite promising antiatherogenic features in 
vitro, vitamin E failed to be atheroprotective in clinical trials in humans for several reasons. 
We highlighted a role of the physiological long-chain metabolite α-13’-COOH of α-TOH as a 
proposed new class of regulatory metabolites which complicate the mode of action of 
α-TOH. Since the formation of α-13’-COOH is probably interindividually different this could 
be a reason for the discrepancies of the results from in vitro and in vivo studies. 
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Manuscript III:  
 
The α-tocopherol long-chain metabolite α-13’-COOH affects the inflammatory 
burst of lipopolysaccharide-activated murine RAW264.7 macrophages. 
 
 Wallert M, Schmölz L, Glei M, Krauth V, Werz O, Birringer M, Lorkowski S 
 
European Journal of Nutrition 
Date of submission: 27th June 2014 
 
Personal contribution to the publication:  
Maria Wallert: Design and performance of RT-qPCR experiments, Cox2 and 
iNos Western blots and Griess assays, writing of manuscript, 
analysis of data, concept development  
Total contribution: 60% 
Lisa Schmölz: Performance of NFκB Western blots, analysis of data and 
evaluation of results  
Michael Glei: Proofreading of manuscript, analysis of data, evaluation of 
results 
Verena Krauth: Performance of PGE2 ELISAs, analysis of data  
Oliver Werz:  Proofreading of manuscript, analysis of data, evaluation of 
results 
Marc Birringer: Proofreading of manuscript, concept development, analysis of 
data, evaluated the results 
Stefan Lorkowski: Design of study, proofreading of manuscript, concept 
development, analysis of data and evaluation of results 
 
Key messages of Manuscript III: 
Inflammatory response as key initiator and driving force for many age associated diseases, 
such as atherosclerosis, is suppressed by α-TOH and its long-chain metabolite α-13’-COOH in 
murine macrophages. A screening of pro- and antiinflammatory markers using RT-qPCR and 
Western blot analyses showed a significant decrease of Il10, Cox2 and iNos by α-TOH and 
more pronouncedly by α-13’-COOH. Likely due to reduction of Cox2 and iNos expression 
production of signal molecules PGE2 and nitric oxide was significantly reduced. Observed 
blocking of inflammatory pathways by α-13’-COOH may be independent from NFκB. Our 
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study sheds new light on α-TOH mode of action in inflammatory pathways in macrophages, 
mediated possibly by its physiological LCM α-13’-COOH which appears to regulate distinct 
pathways. 
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Manuscript IV:  
 
First analysis of α-13’-COOH (13’(6-hydroxy-2,5,7,8,-tetramethylchroman-2-
yl)-2,6,10-trimethyl-tridecanoic acid) a long-chain metabolite  
of vitamin E in human serum. 
 
Wallert M, Ciffolilli S, Galli F, Birringer M, Lorkowski S 
 
Suggested Journal: Journal of Lipid Research - Method Section 
 
Personal contribution to the publication: 
Maria Wallert: Performance of sample preparation, HPLC, GC/MS 
measurements, writing of manuscript, analysis of data, concept 
development, optimization of serum extraction protocol  
Total contribution: 60% 
Silvia Ciffolilli:  Performance of analytical studies (HPLC), preparation of 
samples and measurement of standards, establishment of basic 
protocol 
 Francesco Galli:  Training of methods and supervision of analytical studies, 
proofreading of manuscript, evaluation of results 
Marc Birringer: Proofreading of manuscript, concept development, analysis of 
data 
Stefan Lorkowski: Proofreading of manuscript, concept development, analysis of 
data and evaluation of results 
 
 
Key messages of Manuscript VI: 
Metabolism of vitamin E has not been fully understood yet. In the liver, α-tocopherol is 
metabolized by CYP4F2/CYP3A4-dependent ω-hydroxylation followed by α-oxidation in 
peroxisomes, which results in the formation of intermediate long-chain metabolite 
carboxychromanol (α-13’-COOH). Due to the optimization of the preparation protocols 
regarding enzymatic processing, solvent for organic extraction and the used amount of 
serum, we detected α-13’-COOH in human serum by LC/MS-QTOF at baseline and after one 
week supplementation of RRR-α-TOH for the first time. This represents an important 
analytical advancement in the study of vitamin E metabolism in humans and provides 
evidence for the physiological relevance of this long-chain metabolite.  
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To say it with Eduardo Cardenas´ words: “This is a very exciting time in vitamin E research, 
yet it is evident that we are far away from making the final decision on the benefit vs. risk for 
the potential use of vitamin E in human health” (CARDENAS & GHOSH 2013). The following 
points will give an insight into current problems and obscure or even questionable claims 
about vitamin E to understand its physiological mode of action, its metabolism and the 
discrepancies between in vivo and in vitro results.  
 
4.1 Individual differences in vitamin E utilization and 
metabolism 
Several years ago vitamin E was characterized as an in vitro and in vivo radical chain-breaking 
antioxidant (BURTON & INGOLD 1989). Despite intensive investigations over decades vitamin E 
metabolism and antioxidant dependent and independent properties have not yet been fully 
understood. Nevertheless, vitamin E is widely used as a nutritional supplement (TRABER 2004) 
to prevent age-related diseases such as cardiovascular outcomes, which is probably not 
entirely without side-effects. Although in vitro data and animal trials have shown evidence 
for antiatherogenic effects, confirmation in clinical trials failed (LIBINAKI et al. 2010; 
WALLERT et al. 2014). Since meta-analyses revealed a lack of protection against cardiovascular 
events, a profound understanding of vitamin E metabolism and its biological activity is 
mandatory. Possible explanation can be the difference in dose-effect and also in the form of 
the applied vitamin E (natural or synthetic), e.g. RRR-α-TOH or stereoisomer mixture 
(KEANEY et al. 1994; LIBINAKI et al. 2010).  
For our own in vivo studies we used the natural form RRR-α-TOH for supplementation. After 
one week of supplementation with 1000 IU/d α-TOH serum levels have increased. 
Additionally we detected the LCM of α-TOH, α-13’-COOH, in serum at baseline and in higher 
amounts after supplementation. Next to differences due to the methodical procedure we 
observed interindividual differences in the amount of both α-TOH and α-13’-COOH levels. 
Discrepancies of vitamin E-related outcomes of human in vivo studies may be caused by 
individual differences in intestinal absorption efficiency. As known for drugs and other 
compounds such as β-carotin so-called non-, low or high responder exist (BOREL et al. 1998; 
BROWN et al. 1989; CHEON et al. 2006). Non-responders will likely not benefit from the 
suspected antioxidant properties of vitamin E, thus they could be more susceptible than 
responders to diseases in which free radicals are involved (BOREL et al. 1998). Since vitamin E 
has the highest turnover rate in the liver (BURTON & INGOLD 1989) it may be possible that high 
responders in contrast to “normal” responders tend to degrade vitamin E faster and even 
more and therefore benefit less from vitamin E mediated effects. This could be the reason 
for differences in human supplementation studies. Whereas in non-responders 
supplementation with RRR-α-TOH do not have any effect high-responders may profit from 




Since we assume that the mode of action of vitamin E is mediated by the formation of the 
LCMs, intervention studies with high supplementation of vitamin E possibly should show 
protective effects. A closer look to primary and secondary clinical prevention trials of high 
doses of vitamin E (600 IU - 800 IU) supplementation did not reveal clear results in 
correlation to CVD. The large-scaled Woman’s Health Study (WHS) and the Woman’s 
Antioxidant Cardiovascular Study (WACS) for example only showed invers association in 
secondary outcomes. Secondary prevention with antioxidants of cardiovascular disease in 
endstage renal disease (SPACE) and Cambridge Heart Antioxidant Study (CHAOS) showed 
evidence for an inverse correlation between vitamin E supplementation and CVD. In contrast 
the HDL-Atherosclerosis Treatment Study (HATS) and a large-scaled study from the Medical 
Research Council/British Heart Foundation (MRC/BHF) did not show any effect of natural or 
synthetic vitamin E supplementation. In contrast supplementation of 3200 IU RRR-α-TOH/d 
for 20 weeks suppressed plasma F2-isoprostane, a marker for lipid peroxidation, in 
participants with increased CVD risk (ROBERTS et al. 2007). Hence a more detailed analysis of 
the LCMs formed during vitamin E supplementation in those and further studies would be of 
interest to verify the contribution of the metabolites to vitamin E effects. 
On the other hand the metabolites` biological activity and function is distinct from their 
precursor and could be of interest and will be therefore discussed in the following chapters. 
Vitamin E is the highest accumulated lipid soluble vitamin in plasma and LDL (TRABER 2007). 
Thereby its transport to extra-hepatic tissues is efficient and is the basis for its relevance for 
biological properties such as antioxidant and antiinflammatory effects (LIBINAKI et al. 2010). 
Additionally vitamin E import, export and distribution are regulated by several receptors and 
proteins. Their individual activities in humans are important as been shown for α-TTP 
deficiency in AVED patients which leads to impaired distribution deficiency of α-TOH 
(CARDENAS & GHOSH 2013; TRABER 2007). In these cases it is quite reasonable to supplement 
vitamin E by taking into account the individual therapeutic window (LIBINAKI et al. 2010). 
Based on this it is possible that either absorption or metabolic polymorphisms may exist in 
humans which influence vitamin E metabolism and activity (BOREL et al. 1998). By the 
metabolism of vitamin E hydrophilic metabolites which are called LCMs are formed mainly 
from non-α-TOH isomers. The formed SCMs are excreted via the urine possibly because non-
α-TOH isomers are less active as antioxidants compared to α-TOH (TRABER 2013). The 
excessive intake of vitamin E elevates its own hepatic uptake via SR-B1 (MUSTACICH et al. 
2009) and its subsequent metabolism. The aim of the enhanced degradation of vitamin E is 
likely the protection against toxic accumulation in human organs in contrast to the fat-









Figure 13: Involvement of xenobiotic-associated pathways and enzymes in vitamin E metabolism, 
conjugation and excretion. Metabolism of vitamin E in the liver follows the xenobiotic detoxification 
pathway. First metabolites of vitamin E are formed by CYP3A4- and CYP4F2-dependent ω-hydroxylation and 
further oxidation cycles similar to xenobiotics. Subsequently conjugates are formed via sulfation (SULT), 
glucuronidation (UGT) or with glutathione (GST) to facilitate excretion of the vitamin E metabolites and the 
catabolic end-products in parallel with xenobiotics via multidrug resistance-related proteins (MRP) and MDR 
(JIANG et al. 2007; MUSTACICH et al. 2009; TRABER 2010). 
 
4.1.1 Interaction of vitamin E metabolism with xenobiotic   
detoxification  
The pathway of vitamin E catabolism is in part similar to xenobiotic detoxification. Hepatic 
xenobiotic metabolism occurs in three phases: (I) oxidation, (II) conjugation and (III) 
excretion (TRABER et al. 2011). Each metabolic step involves a subset of hepatic proteins such 
as members of the cytochrome P450 protein family (phase I), sulfotransferases (SULT) and 
glutathione S-transferases (GST) (phase II), and ABC transporters (phase III) (Figure 13). In 
mice these hepatic proteins are upregulated by elevated α-TOH intake (MUSTACICH et al. 
2009; TRABER 2008). Among the phase III transporter systems regulating excretion of 
xenobiotic compounds and their metabolites from the liver the MDRs, such as the xenobiotic 
export transporter MDR1, is of particular importance within the ABC superfamily 
(MUSTACICH et al. 2009; TRABER et al. 2011). Based upon several studies on vitamin E 
metabolism Maret Traber concluded that α-TOH is recognized as a vitamin whereas non-
α-TOH isomers are recognized as xenobiotics which are further metabolized to prepare them 
for elimination (TRABER 2013). Nevertheless our investigations failed to reveal non-α-TOH 
metabolites in human serum. Although non-α-TOH isomers are known to be metabolized 
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fast we only detected α-13’-COOH. The LCMs of δ-TOH, δ-13’-COOH and δ-13’-OH, have not 
been found in human plasma as well as α-13’-OH, the precursor of α-13’-COOH, possibly 
because of fast metabolic degradation or insufficient analytics. Since no standards for γ- and 
β-LCMs are available at present no statement on the existence or accumulation of these 
metabolites in our samplings can be made. Xenobiotic transporters are candidates to be 
involved in the regulation of hepatic TOH concentration and CEHC excretion (TRABER et al. 
2011). One key nuclear receptor in xenobiotic metabolism is among others the PXR (TRABER 
2008). It has been proposed that vitamin E interacts with xenobiotic metabolism via binding 
to the PXR and subsequent formation of the vitamin E PXR/retinoid X receptor (RXR) 
heterodimer which induces metabolism of vitamin E (LANDES et al. 2003; TRABER 2004; 
TRABER et al. 2011). Reports on the regulation of PXR- or CYP3A-dependent metabolism by 
the α-TOH concentration in the liver are inconsistent and therefore the contribution to the 
protection from vitamin E excess needs further investigations. An additional hint for the 
interaction of vitamin E and xenobiotic metabolism is the conjugation, such as sulfation, of 
intermediate and end-products of the vitamin E catabolism as it is known for xenobiotics 
(TRABER 2004; TRABER et al. 2011) (Figure 13). The conjugation of intermediate metabolites 
and catabolic products may be important for intracellular trafficking and trafficking from the 
liver possibly via ABCG2, a transporter responsible for sulfated and glucuronidated 
compounds export (TRABER et al. 2011). 
 
4.1.2 Interaction of the metabolism of vitamin E and K  
Since hepatic CYP4F2 is important for the initial step of vitamin E metabolism it is named 
α-TOH hydroxylase. In addition to vitamin E, CYP4F2 processes long-chain and very 
long-chain fatty acids such as behenic acid (C22:0), lignoceric acid (C24:0) and cerotic acid 
(C26:0) (HARDWICK 2008), oleic acid (C18:1), stearic acid (C18:0) and palmitic acid (C16:0) 
(HSU et al. 2007), and inflammatory response-related (HARDWICK 2008) arachidonic acid 
conversion to 20-hydroxyeicosatetraenoic acid (HETE) (LASKER et al. 2000) and leukotriene B4 
(LTB4) (HSU et al. 2007; KIKUTA et al. 2000). Cytochrome 4F2-mediated hydroxylation is 
inducible by the sterol regulatory element-binding proteins (SREBP) and generates bioactive 
metabolites which act as lipid mediators of signal transduction (HSU et al. 2007; KALSOTRA & 
STROBEL 2006). Parallels also exist between the metabolic pathways of vitamin E and 
vitamin K (TRABER 2010), e.g. side chain ω-hydroxylation by CYP4F2 and the following 
β-oxidation. Further PXR binds vitamin E and vitamin K and activates genes involved in 
xenobiotic detoxification such as CYP3A4 and MDR1 (LANDES et al. 2003; LEHMANN et al. 1998; 
MASUYAMA et al. 2005; TRABER 2008, 2010). Additionally PXR binds the vitamin K metabolite 
menaquinone-4. The PXR/menaquinone-4 complex regulates extracellular matrix and 
collagen formation in osteoblasts (ICHIKAWA et al. 2006). Since vitamin K is important for 
blood coagulation interactions of these vitamins may result in limitation of the active 
vitamin K form by excessive vitamin E which may explain the association of excessive vitamin 
E and coagulation disturbances. Therefore vitamin E has been suggested for therapeutic use 
in patients with increased risk of thrombosis (TRABER 2010). 
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4.1.3 Further metabolic pathway interactions  
As already mentioned in Chapter 1.1.3 parallel intake of α-TOH and other fat-soluble micro-
constituents such as γ-TOH and lutein decrease the absorption of α-TOH by more than 40% 
(γ-TOH) and 20% (lutein). Whereas no significant effects of other carotenoids, such as 
β-carotene and lycopene, on the absorption of α-TOH have been observed in vitro 
(REBOUL et al. 2006). In the case of retinoic acid it has been reported that it inhibits 
absorption of α-TOH by more than 30% in rats (BIERI et al. 1981). As α-TOH is the most active 
isomer, within the group of vitamin E, its optimal absorption under physiological conditions 
is important. Inhibitory effects on the absorption of α-TOH, for example from food 
containing high amounts of inhibitory compounds, have to be considered in the evaluation 
of individual variations in the metabolism of α-TOH. Next to variations in absorption 
subsequent transport of vitamin E and its metabolites is a potential source of individual 
differences. Until now no binding proteins in plasma are known for α-TOH and certainly not 
for the LCM (BJØRNEBOE et al. 1990; TRABER 2013). 
 
4.1.4 Chemical modifications of vitamin E metabolites 
Since the enzymes involved in the metabolism of vitamin E play also a role in several other 
degradation and conversion pathways, such as degradation of isoflavones (TOTTA et al. 2005) 
interference is possible. Individual differences in cytochrome enzyme activity or 
polymorphisms may cause variations in the metabolism of vitamin E and may lead to 
individual differences in the effectiveness of the catabolism of vitamin E and associated 
metabolite formation. The LCMs 9’- and 11’-COOH of γ-TOH and δ-TOH have been found 
only in sulfated form in plasma and liver in rats possibly because the sulfate group protects 
against degradation via β-oxidation, whereas the non-conjugated forms are rapidly 
conjugated (JIANG et al. 2007). In our study glucuronidase and sulfatase treatment has 
increased the amount of α-13’-COOH detectable in human serum (see Manuscript IV page 
82). Therefore we conclude that this LCM occurs as a conjugate in human serum. In fact 
sulfotransferases and sulfatases are important for detoxification. Additionally they may be 
important for the accumulation of the LCM α-13’-COOH at least under supplementation 
conditions (JIANG et al. 2007). Next to the protective role of the sulfate group against 
β-oxidation regulatory functions have been described. For example for the diadzein sulfate 
metabolite which increases estrogen activity (TOTTA et al. 2005) and cholesterol the sulfate 
metabolite stabilizes cell membranes and interferes with signal transduction (JIANG et al. 
2007; STROTT & HIGASHI 2003). Since vitamin E is an important component of cell membrane a 
sulfate metabolite may be also integrated into the cell membrane and may consequently 
stabilize the cell membrane. However, this hypothesis needs further investigations.  
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4.2 Intracellular transport of vitamin E metabolites during 
metabolic degradation  
As described by Mustacich et al. the metabolism of vitamin E takes place in different cell 
compartments, starting at the endoplasmic reticulum, where the first LCM, α-13’-OH, is 
formed by CYP4F2/CYP3A4-dependent ω-hydroxylation. Further, the formation of the LCM 
α-13’-COOH and the following ICMs continues in peroxisomes. Subsequent degradation in 
mitochondria results in the formation of ICMs and SCMs (MUSTACICH et al. 2010). Since these 
catabolic steps occur in three different cellular compartments the formed metabolites have 
to be transported between these compartments. It is possible that different transporter and 
binding proteins exist which bind and transfer the metabolites specifically or unspecifically.  
Since we detected the LCM of α-TOH, α-13-COOH, in human serum (WALLERT et al. 2013 // 
2014) its transport from the liver to the circulation may be regulated somehow. Transport of 
α-TOH from the liver is carried out by α-TTP probably via VLDL which contain α-TOH and 
distribute it to non-hepatic tissues. However, the contribution of VLDL to the secretion of 
α-TOH is not completely understood since brefeldin A, an inhibitor disrupting the Golgi 
apparatus that also affect the secretion of VLDL, does not influence the secretion of α-TOH 
(ARITA et al. 1997). Our knowledge about the distribution of α-TOH may be incomplete, but 
nothing is known about the transport of its LCMs neither within the liver nor into the blood 
and extra-hepatic tissues. It is possible that the transport of α-13-COOH may occur via 
specific binding and transport proteins that have not yet been identified. 
 
4.3 Long-chain metabolites of vitamin E as signaling 
molecules  
Next to the possibility that vitamin E is metabolized to avoid its excessive accumulation it is 
possible that vitamin E procession may form metabolites which further act as molecular 
signals or protecting agents against cell damage caused by free radicals as known from 
α-TOH. Such effects have been described for the SCM of γ-TOH, γ-CEHC, which has 
antiproliferative activity (CARDENAS & GHOSH 2013; CONTE et al. 2004; GALLI et al. 2004b). This 
mayor SCM of vitamin E degradation reaches nanomolar concentrations in serum. The 
phenomenon that short-lived intermediate metabolites or end-products orchestrate signal 
transduction, regulate expression of metabolism-related genes and pathways is known, for 
example, for oxysterols, where the metabolites are also formed in nanomolar amounts 
(SCHROEPFER 2000), and prostaglandins which even act at picomolar levels (BELL-PARIKH et al. 
2003). Additionally, isoprenes are known metabolites that have regulatory properties at very 
low cellular concentrations (FRITZ 2009). 
Lipid mediators, such as ω3-derived lipoxins, resolvins and protectins, occur in 10-100 nM in 
human plasma (SCHROEPFER 2000) and have potent antiinflammatory, pro-resolving and 
tissue-protective effects (BUCKLEY et al. 2014). Resolvin E1 is a metabolite of eicosapentaenoic 
DISCUSSION  | 109 
 
 
acid which regulates for example phagocytosis (HONG et al. 2008). Further, oxysterols, the 
oxidized derivates of cholesterol, function as signaling molecules that regulate a number of 
genes involved for example in cholesterol metabolism and homeostasis via LXR-α and LXR-β, 
SREBP1 and SREBP2 as well as HMG-CoA reductase activity (JANOWSKI et al. 1996; 
KANDUTSCH et al. 1978; LUND et al. 1998; RUSSELL 1999; SCHROEPFER 2000). This is in line with the 
so-called oxysterol hypothesis from Kandutsch et al. postulating that oxysterols and not 
cholesterol itself regulate cholesterol synthesis to a large extent (BJÖRKHEM & DICZFALUSY 
2002; KANDUTSCH et al. 1978).  
In contrast to the variety of investigations on vitamin E isomers, in particular α-TOH, our 
knowledge on LCMs derived from vitamin E and on their regulating activity is rare. Until now, 
only proapoptotic properties of the α-LCMs α-13’-OH and α-13’-COOH by activation of 
caspase-3 and 9 as well as poly (adenosine diphosphate (ADP)-ribose)polymerase (PARP)-1 
cleavage through α-LCMs and δ-LCMs have been described in the human hepatocellular 
carcinoma cell line (HepG2) (BIRRINGER et al. 2010). Additionally, mitochondrial membrane 
potential is reduced whereas ROS formation is increased after treatment of HepG2 cells with 
these LCMs (BIRRINGER et al. 2010). Investigations in neutrophil and human promyelocytic 
leukemia cells showed that generation of LTB4 is decreased by blocking of 5-LOX by 
δ-13’-COOH (JIANG et al. 2011). In addition to these oxidation- and ROS-related effects our 
research focuses the regulation of inflammation and maintenance of lipid homeostasis by 
the α-LCMs. As published recently both α-LCMs, α-13’-OH and α-13’-COOH, increased CD36 
mRNA and protein expression, decreased phagocytosis in human macrophages in much 
lower concentrations and contrary to the metabolic precursor. But accumulation of lipids is 
regulated similarly by all compounds. In addition lipid metabolism related import, synthesis 
and export pathways were analyzed in several cell types and mostly regulations contrary to 
the effects of α-TOH have been observed. The PPARγ target adipophilin (ADRP) is a protein 
associated with triglyceride accumulation. Cytotoxicity caused by excessive accumulation of 
fatty acids can be diminished by PPARγ agonists (RABKIN et al. 2009). We found that the 
α-LCM α-13’-COOH increased the expression of ADRP in contrast to α-TOH (unpublished 
data), whereas stearic acid-related cytotoxicity decreased. Therefore we suggest that 
α-13’-COOH may protect macrophages from fatty acid-induced lipotoxicity and is possibly a 
PPARγ ligand. In addition key players of the LPS-induced inflammatory response of 
macrophages are blocked during α-13’-COOH treatment; this finding is in part consistent 
with results obtained with α-TOH (see Manuscript III page 51). Preliminary data indicate 
involving mitogen-activated protein kinases (MAPK) and other protein kinase (unpublished 
results).  
It is worth to consider whether the physiological effects of intermediate catabolic products 
of vitamin E such as α-13’-COOH are limited because of their rapid metabolism which may be 
triggered by the metabolites themselves. This results in their rapid inactivation as it is known 
for oxysterols (KANDUTSCH et al. 1978). So far, except for the CEHCs, nothing is known about 
the kinetic profiles, stability of the metabolites or their regulatory potential. The catabolic 
end-product of α-TOH metabolism, α-CEHC, is mostly formed after excessive 
supplementation of RRR-α-TOH (TRABER 2013). But information on how far this metabolism is 
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and whether interindividual differences in time and dose of metabolite formation exist, are 
highly required for better understand the metabolism complexity and function of vitamin E. 
Until now, all proposed intermediate metabolites have been found in humans although not 
all have been detected so far. However, individual metabolite formation can vary due to 
differences in enzyme or receptor activity which in turn mediates formation and action of 
the metabolite. Oxysterols for example are known to autoregulate their metabolic fate 
(JANOWSKI et al. 1996). Since α-TOH supplementation leads to increased concentration of 
α-TOH, α-13-COOH and α-CEHC in plasma (SCHULTZ et al. 1995; WALLERT et al. 2013 // 2014), 
α-TOH metabolism may be induced by α-TOH or its metabolites. However, high-dose α-TOH 
injection in rats first increases plasma and liver α-TOH levels which are balanced by the 
massive excretion of the excessive α-TOH (MUSTACICH et al. 2006). Therefore two 
physiological mechanisms that allow the body to deal with excessive α-TOH are proposed: 
that the metabolites regulate their own formation via a feedback loop or trigger directly the 
excretion of α-TOH. 
Depending on the context T3s are sometimes more potent than TOH in their regulatory 
activity. The degradation of T3 is quite similar to TOH as described in Chapter 1.1.3 except 
for the hydrogenisation of the double bonds in the side-chain and the kinetic of degradation. 
The half-lifes of TOH are about 10-20 times higher compared to that of the T3s, because of 
the faster degradation of T3s (KLUTH et al. 2005). Assuming that the metabolites formed are 
responsible for the biological activity of the vitamin E parents more rapid degradation of the 
T3s may also explain their higher biological activity. Since the LCMs and their metabolic 
precursors are structurally similar they may compete, for example, for membrane 
incorporation, transport and binding to receptor proteins and interference with signaling 
pathways. Possibly, the LCMs displace their precursors thus in causing more effective or 
even contrary regulations by the metabolites. This hypothesis may account for cellular and 
physiological effects regulated similarly by both TOH or T3 and their LCMs. For differences in 
their regulating behavior as it has been shown for CD36 by our group (WALLERT et al. 2013 // 
2014), it is more likely that the LCMs have partly different or even contrary effects that are 
exclusively regulated by the metabolites in form of activating or inactivating precursor-
independent signaling pathways. 
 
4.4 Relationship of structure to effectiveness of α-TOH and 
their long-chain metabolites  
Recent studies showed that α-TOH may modulate signal transduction and expression of 
genes involved in inflammation, proliferation and lipid metabolism to name a few. Although 
insufficient data exist to evaluate the biological activity of LCM of α-TOH (α-LCM), α-13’-OH 
and α-13’-COOH, first results suggest that differences in the regulation of scavenger 
receptors and inflammatory markers exist in comparison to α-TOH (WALLERT et al. 2013 // 
2014), see Manuscript III page 51). Since α-TOH and its LCMs, α-13’-OH and α-13’-COOH, 
only differ in the terminal oxidative modification of the side-chain (see Figure 14), we 





Figure 14: Molecular structures of interest. 
 
hypothesized that these hydroxyl and carboxyl groups are required for the recently 
described effects. Further, the eight main vitamin E isomers (α-, δ-, γ-, δ-TOH and T3) vary in 
their antioxidative capacity. Therefore we used the structurally related δ-LCMs δ-13’-OH and 
δ-13’-COOH, which lack two 
methyl groups at the 
hydroxychroman compared 
to α-13’-OH and α-13’-COOH, 
to perform whole-genome 
mRNA expression profiling in 
human macrophages. We 
found that the expression of 
about 650 genes was either 
up- or down-regulated 
significantly by more than 
2-fold (unpublished data). 
The different α- and δ-LCMs caused almost identical patterns of changes in gene expression 
profiles. On the one hand we found genes regulated in the same way as the parent 
compounds α-TOH and δ-TOH and on the other hand contrary and further regulations were 
observed. With these whole-genome expression profiling studies we obtained for the first 
time a broad insight into biological pathways modulated by vitamin E and we confirmed that 
the metabolites exhibit considerable and distinct bioactivity in vitro (unpublished data). To 
support these findings, regulatory mechanisms of the metabolites and their structure-
function relationship were investigated in more detail. We decided to investigate the δ-LCM 
instead of the γ-LCM although the γ-LCM would be of a particular and high interest because 
γ-TOH is the most important vitamin E isomer in US nutrition supplementation and the 
second most common TOH in human plasma that is known for its great biological potency 
(CAMPBELL et al. 2003). As for the α- and δ-LCMs the γ-LCMs are also not commercially 
available and the synthetic production is tricky and requires high amounts of garcinoic acid, 
which has been a limiting factor until now. A more accurate view at the metabolite structure 
reveals that the LCMs are comprised of the chromanol ring system and a branched-chain 
fatty acid-related side-chain. To evaluate the hypothesized structure-function comparison of 
the LCMs α-CEHC and pristanic acid were used as representatives of partial key structures 
(Figure 14). Hence pristanic acid, a branched-chain fatty acid, was used to characterize the 
contribution of the side-chains of α-13’-COOH and δ-13’-COOH. The contribution of the 
hydroxychroman ring system was investigated using the short-chain α-TOH metabolite 
α-CEHC. Furthermore, the δ-LCMs were used for a first insight into the contribution of the 
methylation patterns of the hydroxychroman ring system to the regulation of selected genes 
and protein expression (ADRP and CD36) in macrophages.  
Adipophilin is a lipid droplet-associated protein involved in triglyceride storage in 
macrophages which protects the cells from lipotoxicity (BOSMA et al. 2012). We found that 
δ-13’-OH and δ-13’-COOH regulate ADRP, CD36 and triglyceride synthesis in macrophages to 
similar extent compared to the corresponding α-LCMs. Neither the partial structure of the 





Figure 15: Amplexichromaols - Structures of 
interest for investigating structure-function-
related effects. 
 
hydroxychroman ring nor the carboxylated side-chain, represented by α-CEHC and pristanic 
acid, respectively, regulate ADRP expression in concentrations similar to that of the LCMs. 
Both, the carboxyl and hydroxyl LCMs, were analyzed regarding the structure-function 
hypothesis. As the effectiveness of these LCMs 
was similar in our hands it was assumed that the 
terminal change of the side-chain per se and not 
the type of modification is critical for their 
activity. In contrast investigations by Birringer et 
al. showed significantly enhanced ROS 
formation and decreased mitochondrial 
membrane potential for α-13’-COOH but not for 
α-13’-OH (BIRRINGER et al. 2010). The oxidative 
status of the side-chain modification also 
determines the cytotoxic properties of the 
LCMs. The EC50 value in THP-1 macrophages is 
7.4 µM for the carboxychromanol α-13’-COOH, 
whereas no EC50 value could be observed for the 
hydroxychromanol α-13’-OH (WALLERT et al. 
2013 // 2014). Analysis of further compounds 
with multiple side-chain oxidations or non-oxidized side-chains such as nitration are 
therefore responsible. Since T3s are known to act more potently in some conditions 
compared to TOHs it could be important to investigate these structures in a comparable 
setting. Since the metabolites only differ in the T3-specific double bonds the importance of 
side-chain saturation in mediating biological activity could be ascertained. Further the 
investigation of both the side-chain saturation and the terminal oxidation status of the side-
chain in parallel may be possible by using new amplexichromanol compounds (Figure 15) 
such as α-amplexichromanol, δ-E-amplexichromanol or δ-E-desoxyamplexichromanol 
(LAVAUD et al. 2013). 
Taken together these results provide clear evidence that both (i) the whole molecule 
comprised by the hydroxychroman ring and the side-chain, and (ii) the oxidation of the side-
chain carrying a hydroxyl or carboxyl group is mandatory for the biological functions and 
specificity of these LCMs. These findings also suggest that a specific receptor exists which 
binds the α-LCMs and δ-LCMs, but neither the metabolic precursors α-TOH and δ-TOH nor 
the SCMs to modulate further signaling pathways. However, it is yet not clear, whether the 
ICMs still exhibit bioactivity similar to that of the LCMs.  
 
 
4.5 Membrane incorporation of vitamin E and long-chain 
metabolites  
Transversal diffusion is common for all lipophilic membrane components. Differences in 
transversal diffusion are known for vitamin E isomers but nothing has been described for the 
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metabolites so far. But cellular uptake by passive diffusion through the membrane is 
probably unlikely due to the chemical structure and size of the vitamin E molecules. Next to 
the transversal diffusion TOH and T3 are known to be incorporated into cell membranes and 
to be subject to lateral diffusion (Chapter 1.1.4.3). But nothing is known about diffusion 
processes of vitamin E metabolites yet. 
Compared to 15 mol% cholesterol, for example in the Golgi apparatus, the amount of 
vitamin E in membranes is much lower, 0.1 mol% up to 1.5 mol% (SONNEN et al. 2005). 
Therefore the effects of TOHs and T3s on membrane fluidity may be entirely negligible at 
physiological concentrations (SONNEN et al. 2005). Additionally, vitamin E isomers diffuse 
lateral in biological membranes independently from their methylation pattern or the 
saturation of the isoprenoid side-chain, which suggests that the partly recommended higher 
antioxidant activity of T3s compared to TOHs is not based on the higher mobility of T3s 
(SONNEN et al. 2005). Furthermore, the cholesterol content decreases and the temperature 
increases lateral diffusion, respectively, whereas the influence of temperature is much more 
pronounced (SONNEN et al. 2005). The differences between TOHs and T3s in membranes are 
caused by the reorientational dynamics of T3s and a higher ordering effect of TOHs in the 
lipid phase (SONNEN et al. 2005). Membrane incorporation and lateral diffusion similar to 
vitamin E isomers may be possible for the LCM α-13’-OH and α-13’-COOH because of existing 
structural similarities to α-TOH. Regarding to the terminal oxidation possibly more space will 
be needed for α-13’-COOH in comparison to the non-oxidized precursor during the 
incorporation into the cell membrane. The side-chain of α-TOH has an unpolar terminal 
methyl group. In comparison the terminal carboxyl group of the α-13’-COOH is polar which 
probably requires more space within the membrane. It is conceivable that the space needed 
by α-13’-COOH within the membrane is between α-TOH and α-T3. Consequently the 
negative curvature stress caused by α-13’-COOH is probably also between both compounds 
(SEN et al. 2007).  
The question is whether cellular uptake of the metabolites is required for affecting cellular 
signaling. Even in the case that the metabolites are not taken up by the cells this does not 
necessarily mean that the metabolites are unable to exert specific effects on cells. Binding of 
the metabolites to putative cell surface receptors may be sufficient to mediate outside-in 
signaling even if the compound is not taken up. Recently published data on the biological 
activity of the LCMs and further unpublished data outlined here provide evidence for a 
specific response of the cells to the metabolites and suggest that a receptor exists that 
specifically binds and mediates a specific regulatory response of the cells to the α-LCM 
(WALLERT et al. 2013 // 2014). 
 
4.6 Does membrane-located receptor binding mediate the 
effects of the long-chain metabolites?  
For several years vitamin E has been widely used as an antioxidant and protective agent to 
prevent cardiovascular diseases. Next to its antioxidative properties, vitamin E has been 
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suggested to modulate gene expression as summarized in Manuscript II (page 42). We 
suggest that the LCMs of vitamin E formed during vitamin E degradation represent a new 
class of signaling molecules mediating some of the effects seen with the parent compound 
on gene expression and cellular signaling (ZINGG 2007). But its function and mode of action is 
mostly unknown. In vitro studies on macrophages revealed that the metabolites affect 
expression of several genes as well as cellular processes such as scavenger receptor-
mediated endocytosis and phagocytosis (WALLERT et al. 2013 // 2014). These results raise the 
question whether the metabolites may exhibit physiological functions not only in liver cells, 
where they were formed and detected first (BIRRINGER et al. 2010), but also in extra-hepatic 
tissues. Distribution of vitamin E, predominantly α-TOH, from the liver possibly by VLDL and 
its further transport to extra-hepatic tissues is widely known (for details see Chapter 1.1.2 of 
the introduction). But, transport of vitamin E metabolites has not yet been investigated. 
However, so far neither a specific receptor mediating the effects of vitamin E nor a 
physiological role of this vitamin, except for its function as a fertility factor in rats (EVANS & 
BISHOP 1922), have been unraveled. Therefore, the identification of a cellular receptor that 
specifically binds LCM and further mediates the regulatory signaling of the α-LCM is of 
particular interest.  
Apart from α-TTP only TBP has been identified as cytosolic α-TOH binding protein, which 
facilitates incorporation of α-TOH into organelles and its transfer between membranes of 
intracellular organelles (DUTTA-ROY et al. 1993). Additionally human TAP is involved in lipid 
and TOH metabolism (ZINGG et al. 2010b) as well as intracellular TOH-related functions 
(STOCKER et al. 1999). Therefore it is obvious that a peripheral or integral receptor located at 
the cell surface or within the membrane may exists which either binds and further transfers 
the metabolites of vitamin E inside the cells to enable signaling function or mediates the 
signaling via pathways that need to be identified. This hypothesis is supported by findings 
obtained from primary human coronary artery smooth muscle cells (HCA-SMC) were the 
recombinant human tocopherol associated protein (hTAP) 1 may act as a sensor for lipids 
within the cell membrane. Subsequent transport of the lipids affords PI3K-mediated 
signaling and gene expression. α-Tocopherol and α-TP induce PI3Kγ-mediated signaling by 
binding of hTAP1, which further stimulates PI3Kγ activity (ZINGG et al. 2014). Vitamin E is 
acting probably by modulating specific and non-specific protein-membrane interactions, 
which enable further enzyme translocation to the plasma membrane, e.g. induced by 
phosphorylation, or by direct binding of the enzymes to receptors, structural proteins or 
transport proteins, such as lipoproteins or the hydrophobic ligand-binding proteins α-TTP 
and TBP (STOCKER et al. 1999; ZINGG 2007). As summarized by Zingg signal transduction 
mediated by vitamin E may be diverse and may lead to intracellular distribution of specific 
messenger lipids to enzymes and organelles (ZINGG 2007).  
Vitamin E and its LCMs are lipid soluble compounds. Therefore they may traverse biological 
membranes by simple diffusion; in fact, however, they may require membrane receptors or 
transporters or a combination of both, as described for free fatty acids (BONEN et al. 1998; 
ZINGG 2007). Fatty acid transporters, such as plasma membrane located fatty acid binding 
protein (FABPpm), fatty acid translocase (FAT) and fatty acid transporter protein (FATP) 
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(BONEN et al. 1998) are potential transporters for vitamin E and its LCMs. 
Since lipid G-protein-coupled receptors (GPCR) mediate several effects in cells such as cell 
migration, phagocyte activation by chemotaxis, degranulation, superoxide generation and 
vascular endothelial permeability (SUN & YE 2012). In these processes some genes are 
involved that are regulated by α-TOH (ZINGG et al. 2010b) and T3 (SYLVESTER et al. 2002). 
Therefore their involvement in LCM-mediated effects needs to be considered. Several GPCR 
agonists are known to trigger monocyte/macrophage inflammatory response, such as the 
platelet-activating factor (PAF) (LATTIN et al. 2007). In murine macrophages PAF antagonists 
inhibit LPS-induced iNos mRNA expression and nitric oxide production and reduce synthesis 
of nitric oxide in various animal models of endotoxemia (SZABÓ et al. 1993). As shown in 
Manuscript III α-13’-COOH blocks LPS-induced expression of iNos and Cox2 mRNA and 
protein as well as production of nitric oxide and PGE2 in RAW264.7 macrophages. 
Furthermore LTB4-activated nitric oxide production in trypanosoma cruzi-infected murine 
macrophages is mediated by the LTB4 receptor-dependent pathway which is partially 
blocked by a PAF receptor antagonist UK-74505 (LATTIN et al. 2007; TALVANI et al. 2002). 
Based on these data it is possible that α-13’-COOH acts as a PAF antagonist and interferes 
with LTB4, but this needs further investigation. Since GPCR signaling is responsible, for 
example, for alternative pathways of cell activation, such as TLR signaling activated by LPS 
(LATTIN et al. 2007), lipid soluble α-13’-COOH may act as a lipid mediator which binds to a 
GPCR (MURAKAMI 2011). This hypothesis is supported by findings obtained from peritoneal 
macrophages of heterotrimeric G protein knockout mice Gαi2
-/- show reduced production of 
inflammatory marker such as tumor necrosis factor (TNF)-α and thromboxane (TX) B2 
(FAN et al. 2005). In contrast stimulated splenocytes of these knockout mice showed 
increased production of inflammatory markers (FAN et al. 2005). Further, interaction of 
heterotrimeric G proteins and histone deacetylase (HDAC) type 5 has been shown 
(LATTIN et al. 2007; SPIEGELBERG & HAMM 2005). Histone deacetylases act as potent and 
selective negative regulators of the proinflammatory response in macrophages e.g. by 
blocking the ability of LPS to induce Cox2 mRNA in Hdac-8 overexpressing RAW264.7 
macrophages (AUNG et al. 2006). In contrast, HDAC inhibitors induce hyperacetylation of 
histone H4 and stimulate expression of the proinflammatory cytokine IL-8 in SV-40 
transformed bronchial epithelial cells (BEAS-2B) (TOMITA et al. 2003), whereas HDAC 
inhibitor-treated rats show reduced expression of IL-1β and TNFα (WANG et al. 2014). Taken 
together inconsistent data exist whether HDAC inhibitors enhance or decrease inflammatory 
response. However, vitamin E metabolites are structurally putative HDAC inhibitors 
(DASHWOOD & HO 2007). Since the α-LCMs block LPS-induced inflammatory response we 
investigated if the α-LCMs act as HDAC inhibitors in vitro (unpublished data). Since no data 
supporting this hypothesis have been obtained HDAC regulation mediated by α-LCM remain 
unclear. 
G-protein coupled receptors are involved in several signaling pathways including PKA, PKB, 
PKC and phospholipase (PL) Cβ (Figure 16). Following the PLCβ pathway downstream, rat 
sarcoma (Ras), rapidly accelerated fibrosarcoma (Raf) and extracellular-signal regulated 
kinases (ERK1/2) are activated by phosphorylation. We already know that α-13’-COOH 





Figure 16: Suggested G-protein coupled receptor related signaling by α-13’-COOH. 
enhances ERK1/2 phosphorylation in human fibroblasts. Starting from ERK1/2 subsequent 
cPLA phosphorylation is suggested. Since ERK1/2 is also regulated by PKA and subsequent 
Ras-related protein (Rap)/Raf signaling the involvement of PKA is assumed. Whereas PLCβ 
and PKA activate ERK1/2, PKC blocks it by interacting with Ras. Protein kinase B, also termed 
Akt, or further serine/threonine kinases maybe regulated through phosphatidylinositol-
mediated signaling (BEAULIEU et al. 2009). α-Tocopherol or α-TP binding to CD36 may trigger 
phosphorylation of Akt (ZINGG et al. 2010a). Since α-13’-COOH upregulates CD36 
(WALLERT et al. 2013 // 2014) the interaction of this LCM and Akt is suggested. First 
experiments gave a hint that glycogen synthase kinase (GSK) 3β phosphorylation at serine 9 
is inhibited by α-13’-COOH (Figure 16, unpublished results). Glycogen synthase kinase 3β and 
the subunit GSK3α have been originally associated with the regulation of glycogen 
metabolism (FRAME & COHEN 2001). These kinases are constitutively active and can be 
inactivated by phosphorylation of single serine residues, serine 21 (GSK3α) and serine 9 
(GSK3β), of their respective regulatory amino-terminal domains (BEAULIEU et al. 2009; 
FRAME & COHEN 2001). Since GSK3β is involved in phosphorylation and therefore 
destabilization of β-catenin it plays a key role in Wnt/β-catenin signaling via lymphoid 
enhancing factor (LEF) 1 and T cell factors (TCF) and subsequent signal transduction (WU & 
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PAN 2010). The possible involvement of α-13’-COOH in GSK3β signaling requires its 
interaction with the key signaling regulator of GSK3β Wnt. Active unphosphorylated GSK3β 
further activates NFκB, the main target of inflammatory response. Since we have shown that 
α-13’-COOH does not block LPS-induced NFκB p65 subunit translocation to the nucleus the 
blocking of GSK3β phosphorylation by α-13’-COOH has been hypothesized. In contrast, 
α-13’-COOH significantly reduced inflammatory markers such as Cox2 and iNos mRNA and 
protein expression as well as subsequent PGE2 and nitric oxide production (see Manuscript 
III). One explanation can be the involvement of a further inflammation associated nuclear 
receptor named activator protein (AP)-1. The term AP-1 comprises homo- or heterodimeric 
protein complexes formed by Jun, Fos and cyclic AMP-dependent transcription factors (ATF). 
This is in good agreement with the fact that ERK1/2 and further MAPK targets regulate AP-1. 
α-Tocopherol prevents macrophage foam cell formation by down-regulating scavenger 
receptor CD36 which is involved in the uptake of oxidized LDL (DEVARAJ et al. 2001; 
RICCIARELLI et al. 2000). Further, γ-TOH induces expression of adiponectin in C57BL/6J-mice at 
both transcriptional and circulating protein level (LANDRIER et al. 2009). Both genes are under 
control of PPARγ, a ligand-regulated transcription factor that plays an essential role in 
energy metabolism. In vitro, the amount of adiponectin mRNA was diminished in 3T3-L1 cells 
when coincubated with GW9662, a PPARγ antagonist. Two earlier studies demonstrated that 
γ-TOH activates PPARγ in the human colon cancer cell line SW480 (CAMPBELL et al. 2003), and 
induces expression of PPARγ and transglutaminase-1 protein (a target gene of PPARγ) in 
keratinocytes, respectively (De Pascale, M Clara et al. 2006). A paper by Fang et al. described 
T3 to activate different isoforms of PPARs thereby reducing blood glucose levels and insulin 
sensitivity of diabetic Db/Db mice (FANG et al. 2010). To sum up, existing studies indicate that 
all vitamin E isomers, except α-TOH, act as PPARγ agonists and induce PPARγ-dependent 
downstream mRNA and protein expression. Interestingly, α-TOH is the only vitamer which is 
not readily metabolized and excreted, and is the most abundant isomer in plasma. We 
therefore considered whether PPARγ activation is mediated by α-TOH metabolites, in 
particular LCMs rather than by α-TOH itself. As shown in Manuscript I the scavenger receptor 
CD36, the non-feedback regulated oxLDL importer, is up-regulated by both α-LCMs (page 33) 
and δ-LCMs (unpublished data). The initiation of signal transduction after binding to CD36 is 
known for oxLDL and fatty acids (ZINGG et al. 2010a). Upon binding of α-TP to CD36 direct 
CD36 ubiquitination or its internalization via endocytosis is possible (ZINGG et al. 2010a). Next 
to CD36 ADRP is regulated by the LCMs (unpublished data). Since these are target genes of 
the nuclear receptor PPARγ we suggested that the LCMs are natural PPARγ ligands. In 
contrast microarray analyses showed that other common PPARγ-related genes are not 
regulated. To evaluate the LCMs in detail regarding their PPAR isoform agonist activity 
profiling expression in in vitro studies or monitoring of their activity via luciferase-based 
promoter reporter assays are needed. 
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4.7 Problems and challenges of the in vitro studies  
4.7.1 Challenge of reproduction of in vitro results 
The reproducibility of results gained from both in vitro and in vivo studies is sometimes 
difficult. The reasons for this are diverse and may refer to the type (ZINGG et al. 2010a) and 
conditions of the cell culture, the used compounds (ZINGG et al. 2010b), the senescence of 
cells, spontaneous mutation or invisible contaminations, such as mycoplasmas within cell 
lines. Further, the supplier and the formulation of the compounds, duration time of 
experiments, and the performer may influence the results, to name only a few. 
Concentrations used to perform experiments are a highly discussed and important topic. In 
general physiological concentrations should be used, if possible. But a closer look to 
published data confirms that compliance to this general rule is rare. Therefore the 
physiological relevance of these data is dubious (ZINGG et al. 2010b). The use of higher 
concentrations for compounds in vitro than they occur physiologically in vivo is sometimes 
unavoidable. For example transport mechanisms occurring in vivo sometimes are not 
available in cell culture experiments, as discussed for α-TP uptake (ZINGG et al. 2010a), which 
justifies higher doses during incubation experiments in which to finally achieve comparable 
effective compound concentration within the cells.  
If a new compound is investigated sometimes higher concentrations have to be used to get a 
first insight into the effects mediated by this compound. In the case of the newly identified 
LCM of α-TOH the best mode of application for the metabolite is not known. Therefore it 
needs to be investigated how different formulations may affect the ‘bioactivity’ and 
bioavailability of the metabolites in the cell culture as this may help to develop enhanced in 
vitro models that better reflect the situation in vivo. To closely imitate physiological 
conditions for lipid soluble compounds the application combined with serum or any other 
“carrier”, such as lipids, lipoproteins or serum albumin is probably the best. During in vitro 
experiments an important point in general is the uptake of compounds into the cells. In the 
case of vitamin E isomers different protocols have been used, but not so far for its LCMs. The 
application of TOHs in cell culture experiments is frequently requested. Approved 
applications to ensure an adequate uptake of TOHs are coupling to serum (WU et al. 2005), 
or dissolving in either ethanol (RICCIARELLI et al. 2000) or dimethyl sulfoxide (DMSO) 
(BIRRINGER et al. 2010). Wu and colleagues have shown, for example, that TOH incubation in 
micromolar concentrations results in picomolar amounts of TOHs detectable in ECs 
(WU et al. 2005). We expect similar uptake mechanisms for TOH and LCMs for macrophages, 
but this needs further verification.  
It is also not known which cellular levels of the metabolites can be achieved under the 
current experimental conditions (WALLERT et al. 2013 // 2014). However, significant 
differences in intra- and extracellular concentrations of metabolites are very well known. 
The LCMs of α-TOH were found only in relatively low concentrations in the cytoplasm of liver 
cells, but concentrations in organelles, such as microsomes, peroxisomes and mitochondria, 
are much higher (MUSTACICH et al. 2010). Since α-13’-COOH was measured in nanomolar 
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range in serum (WALLERT et al. 2013 // 2014), much higher concentrations up to lower 
micromolar range may occur at tissue or cellular level. Therefore it is probably appropriate 
to apply higher concentrations for cell culture experiments. Besides, it is a common 
observation that higher concentrations of bioactive molecules are required in vitro than they 
are likely available physiologically, as studies on regulatory features of oxysterols, 
prostaglandins and glitazones show (CHINETTI et al. 2001; JANOWSKI et al. 1996; TAM et al. 
2006). In addition previously established conditions serve often as orientation for other 
research groups to achieve better comparability between results.  
 
4.7.2 Species specific vitamin E metabolism – possible reasons for 
discrepancies of supplementation studies   
Animal models have been used for decades as model systems to understand mechanisms 
and disease development in humans because of many similarities regarding metabolism and 
pathologies. Furthermore, breeding of knockout rodents for example yields highly useful 
disease models within an acceptable time which is not practicable in humans. For the 
evaluation of the developmental neurotoxicity in humans for example laboratory animals, 
rodents and non-human primates, are quite suitable in some cases, such as 
motivational/arousal, cognitive, motoric and social capacities (STANTON & SPEAR 1990). But, 
recent data suggest that animal models used to understand the initiation or progression of 
diseases in humans is likely not the best choice for all conditions (SEOK et al. 2013). Because 
of anatomical, physiological and developmental differences between species some effects 
observed in animals are not transferable to humans (ANDERSON et al. 2009). Therefore cross-
species comparisons can cause problems including species differences in pharmacokinetics, 
developmental stage at exposure and assessment, or underlying mechanisms (STANTON & 
SPEAR 1990). Discrepancies can vary extremely dependent on the observed disease, end-
point analysis, timing of sample acquisition and dosing of drugs (SEOK et al. 2013). Next to 
obvious differences, less striking species differences for example in peptide structure 
resulting in different substrate specificities between humans and mice have been described 
(KALUPOV et al. 2009). For several reasons previous studies have failed to systematically 
evaluate the suitability of murine clinical models mimicking human inflammatory diseases 
particularly in relation to the inflammatory response on the molecular level (SEOK et al. 
2013). By analyzing published studies on the major pathways involved in the inflammatory 
response, Seok et al. focused high discrepancies between human and mice with respect to 
the individual gene activation in either direction or magnitude, such as the TLR pathways 
(SEOK et al. 2013).  
Many studies elucidating vitamin E metabolism were performed in human cell lines 
(BIRRINGER et al. 2002b; SONTAG & PARKER 2002), mice (BARDOWELL et al. 2012; JOHNSON et al. 
2012; KLUTH et al. 2005; MUSTACICH et al. 2009; ZHAO et al. 2010) or rats (MUSTACICH et al. 
2006) and only a few in humans (ZHAO et al. 2010). Regarding the probably most important 
enzyme in vitamin E metabolism, the conserved ω-hydroxylase (PARKER & MCCORMICK 2005) 






Figure 17: Similarities and differences in human and rodent vitamin E metabolism. In general the 
metabolism of vitamin E in rodents and humans is processed by similar enzymes: α-TTP is the main binding 
protein for vitamin E in the respective species, CYPs for the formation of LCMs, and MRD family proteins 
are responsible for excretion of conjugated catabolic end-products mainly via urine. Metabolites formed by 
ω-hydroxylation and oxidation were detected in the liver and partly in serum of rodents and humans. The 
regulation of the vitamin E metabolism by PXR binding is suggested. (JOHNSON et al. 2012; KLUTH et al. 2005; 
MUSTACICH et al. 2009; WALLERT et al. 2013 // 2014) 
 
 
CYP4F2 in humans, Cyp4f14 was found in mice as an ortholog with >80% sequence identity 
(BARDOWELL et al. 2012). A second hydroxylase, CYP3A4 in humans or rather Cyp3a11 in mice 
(BARDOWELL et al. 2012), is suspected to be involved in TOH and T3 degradation.  
Physiological basic α-TOH serum level in humans are around 25 µM and may reach after 
supplementation a maximum of 70 µM followed by a steady state of uptake and excretion 
(SCHULTZ et al. 1995). In contrast, Mustacich and co-workers found a maximum serum 
concentration of 483 μM after subcutaneous α-TOH injections for six days (10 mg/100 g 
body weight) in rats (MUSTACICH et al. 2006). Additionally the catabolic end-product α-CEHC 
increased up to 7.4 μM; this is several times higher as it is reachable in humans. Although 
subcutaneous injection has been used in many animal studies, it is not really comparable to 
oral supplementation and the differences in serum concentrations are enormous. After the 
sixth day of injection both α-TOH and α-CEHC serum and liver concentrations decreased 
steadily in the study of Mustacich et al. The authors hypothesized that enhanced 
metabolism and biliary excretion, as it is known for humans, are reasons for this 
counterbalancing that correlates with the accumulation of metabolic intermediates. In 
parallel the first hepatic LCM formed in the catabolism of α-TOH, α-13’-OH, with is 
detectable in rats at baseline, increased up to the third day and subsequently decreased 
after reaching a steady state within the next days. The SCM 5′-α-CMBHC behaves similarly 
following supplementation, with the difference that it was not detected at baseline 
(MUSTACICH et al. 2006).  
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The exporter MDR1 and the murine ortholog Cyp3a11 of the human CYP3A4 hepatic enzyme 
(MUSTACICH et al. 2006; MUSTACICH et al. 2009) increased under supplementation with α-TOH 
in mice (MUSTACICH et al. 2009) and rats (MUSTACICH et al. 2006), but α-TTP and CYP4F2 were 
not regulated (Figure 17). Whereas humans and rats have two MDR isomers, MDR1 and 
MDR3, mice have Mdr1a and Mdr1b and the MDR3 ortholog Mdr2 which is important for 
basal biliary α-TOH excretion (MUSTACICH et al. 1998; MUSTACICH et al. 2009). Mustacich and 
coworkers conclude that this regulation shows that apart from some species-related 
discrepancies the α-TOH mechanism seems to be conserved across species (MUSTACICH et al. 
2009). But some data exist suggesting that this cannot be generalized for all vitamin E 
isomers. γ-Tocotrienol, for example, induced CYP3A4 in human HepG2 cells but not the 
analogous Cyp3a11 mRNA in mice liver possibly because activation of the PXRs, which is 
involved in vitamin E metabolism, shows species-specific differences (KLUTH et al. 2005) (see 
Figure 17). It has been suggested further that in mice Cyp3a11 might not be the enzyme 
which metabolizes γ-T3 (KLUTH et al. 2005). Therefore the participation of CYP4F2 needs to 
be investigated in more detail (KLUTH et al. 2005). 
Vitamin E catabolism results in the urinary metabolite CEHC which is mostly conjugated. 
Recently metabolites α-CEHC glycine, α-CEHC glycine glucuronide, and α-CEHC taurine were 
found in both mice and humans, whereas α-CEHC sulfate and α-CEHC acyl glucuronide were 
present in human urine only (JOHNSON et al. 2012). This further shows the differences 
between murine and human vitamin E metabolism (JOHNSON et al. 2012) (Figure 17). 
However, there is a large interindividual variability in α-TOH metabolism in humans, too. 
Whereas α-CEHC glucuronide and sulfate are metabolites that are always detected, α-CEHC 
taurine, α-CEHC glycine, and α-CEHC acyl glucuronide were present in about 50-90% of the 
investigated volunteers (JOHNSON et al. 2012). Johnson and coworkers concluded that 
polymorphisms in drug-metabolizing enzymes and transporters and/or competitive co-
metabolism of endogenous metabolites by gut microflora may be the reason for these 
differences (JOHNSON et al. 2012). To what extent the formation of the LCMs is subject to 
individual variations needs further investigations. Individual pharmacokinetics and 
differences in formation of these metabolites in addition to the latest findings by our group 
(BIRRINGER et al. 2010; JIANG et al. 2008; WALLERT et al. 2013 // 2014) suggest a physiological 
and probably pathophysiological importance for the metabolites. To answer some open 
questions, supplementation studies with naturally-occurring RRR-α-TOH over weeks using 
different doses to study saturation kinetics of the metabolite in human plasma and the half-
life time and plasma levels of the LCMs have to be performed. First data for α-13’-COOH 
suggest that plasma levels of this LCM vary following supplementation in individuals 
(unpublished data), which may be very important compared to the fact that α-TOH levels are 
known for its small variations. This is of further fundamental importance when discussing 
the influences of vitamin E on pathological conditions or rather the progression of disease 
such as atherogenesis and diabetes and how vitamin E acts on the systemic and cellular 
level. Hence, the ratio of the metabolite and α-TOH plasma concentrations may be relevant. 
Studies in humans after one week supplementation with 1000 IU/d α-TOH showed a fivefold 
increase in LCM α-13’-COOH concentration in serum (unpublished data), whereas α-TOH 
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increased only up to 3-fold suggesting higher relevance for the metabolite after 
supplementation. Further findings about maximum plasma levels of α-13’-COOH or if a 
steady state is achieved after supplementation may give a hint for its physiological 
relevance. Both healthy humans and AVED patients, characterized by an α-TTP deficiency 
resulting in lower α-TOH serum level due to disturbed α-TOH distribution, are of particular 
interest for these metabolic studies. Since nothing is known about the release of 
α-13’-COOH into the serum analyzing blood of AVED patients may give a hint whether α-TTP 
acts as a transport protein for this metabolite. In this case the serum levels of α-13’-COOH 
will not increase independently from α-TOH, if nonetheless the level increase after vitamin E 
supplementation further transport proteins or mechanisms distinct from α-TTP have to be 
proposed for the transport of LCM and their release into the blood. 
Independent of the investigated species conclusions or recommendations should be based 
on more than one disease model, to provide adequate information and representations of 
disease progression (MURRAY & FRENK 2008). In this context Fiume and coworkers reported 
that α-TOH absorption studies and retention in serum did not show satisfactory correlation 
between human and rats which caused underestimation of the potency of free TOH in 
humans (FIUME 2002). Development of alternative artificial human models to replace animal 
studies for in vitro studies to investigate disease-related cell types or tissues has been 
promoted over the last years (HUH et al. 2010). 
 




Atherosclerosis and its complications such as stroke and myocardial infarction are next to 
cancer the leading cause of death in Western industrialized societies. In Germany about 40% 
of total mortality in 2012 was related to cardiovascular events (Statistisches Bundesamt 
2012). This will increase further in the next years (HONARBAKHSH & SCHACHTER 2009). Use of 
vitamin E for prevention of cardiovascular diseases (CVD) was first mentioned in the 1950’s 
by Dr. Even Shut (CHAN 1998). Since that time, vitamin E has been known as an antioxidant 
and has been investigated for decades in regard to these properties. Many studies showed 
that vitamin E exhibits antioxidative capacity in vitro (VAN DAM et al. 2003). Since age-related 
diseases, such as CVD, cancer and Alzheimer disease, are associated with oxidative events, 
vitamin E intake was promising in preventing these diseases or at least slowing down their 
progression. Based on promising results in in vitro and animal studies several large-scale 
human intervention studies were initiated and followed up over years. In regard to 
preventing cardiovascular complications these studies revealed controversial results and 
failed to demonstrate clear invers correlations or positive effects of vitamin E 
supplementation (WALLERT et al. 2014). Reasons for the poor outcomes are complex. Apart 
from differences in study designs, such as the selection of volunteers, the sizes of cohorts, 
doses and duration of supplementation and application form of vitamin E, individual 
differences in vitamin E metabolism may be responsible for different outcomes. The 
importance of the metabolic differences needs to be clarified further.  
The term vitamin E describes a group of isomers within α-, β-, γ-, δ-tocopherol (TOH) and the 
respective tocotrienols are the most important ones. The isomers differ in methylation 
patterns of the hydroxychromal ring system and saturation of the side-chain. In the liver 
vitamin E metabolism occurs in three compartments: endoplasmic reticulum (ER), 
peroxisomes and mitochondria. In ER the long-chain metabolite (LCM) α-13‘-OH is formed by 
CYP4F2/CYP3A4-dependent ω-hydroxylation followed by α-oxidation which results in the 
formation of α-13‘-COOH. Two subsequent β-oxidation steps in peroxisomes and three 
β-oxidation steps in mitochondria form ICMs and finally SCMs which are mainly excreted via 
urine. Although many of these metabolites have been detected in humans, nearly nothing is 
known about their physiological or pathophysiological relevance. 
We detected considerable amounts of the LCM α-13‘-COOH in serum of healthy humans by 
LC/MS-QTOF. Due to optimization of the preparation protocols regarding enzymatic 
processing and organic extraction we detected α-13’-COOH in human serum in nanomolar 
concentrations. This finding provides evidence for physiological relevance of this LCM. After 
one week of supplementation with 1000 IU/d RRR-α-TOH the concentration of α-13‘-COOH 
increased at least fivefold. We assume that the formation and the effects of α-13‘-COOH are 
different between individuals, which could possibly explain the controversial outcomes from 
human intervention studies.  
Apart from antioxidative properties further independent effects of α-TOH have been 
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reported (AZZI et al. 1995). Therefore we investigated the effects of the α-LCMs, which have 
been synthesized from the African bitter nut garcinia kola, for antioxidative independent 
effects. As macrophages play a key role in inflammation and atherosclerosis, human and 
murine macrophages were used as model systems to investigate the molecular modes of 
action of α-TOH and the respective LCMs α-13’-COOH and α-13’-OH.  
Scavenger receptor CD36 takes up modified lipoproteins and plays therefore a key role in 
maintaining cellular lipid homeostasis (DEVARAJ et al. 2001). By using quantitative real-time 
PCR and flow cytometry we found an induction of CD36 mRNA and protein expression by 
α-13’-OH and α-13’-COOH, whereas the precursor α-TOH decreased both kinds of 
expression. Pretreatment of macrophages with the LCMs followed by oxidized LDL (oxLDL) 
incubation significantly increased the oxLDL-related CD36 protein expression, whereas 
α-TOH did not. Apart from the scavenger receptor-mediated uptake, oxLDL particles can be 
internalized by macrophages via phagocytosis. Flow cytometric analyses with fluorescent 
microbeads showed that the LCMs inhibited phagocytosis in contrast to α-TOH (IZGÜT-
UYSAL et al. 2004). Although the LCMs increased CD36 expression net uptake of fluorescent 
oxLDL and accumulation of neutral lipids were decreased by α-13‘-OH, α-13‘-COOH and 
α-TOH, possibly by a balancing of the lipid import mechanisms involving CD36 receptor and 
phagocytosis (WALLERT et al. 2013 // 2014). 
Next to foam cell formation, inflammation plays a pivotal role in atherogenesis. 
Investigations of bacterial lipopolysaccharide (LPS)-activated murine macrophages by using 
quantitative real time PCR showed that LPS-triggered upregulation of key inflammatory 
markers, such as cyclooxygenase 2 (Cox2) and inducible nitric oxide synthase (iNos), were 
significantly blocked by α-13‘-COOH, but not by α-TOH treatment. Similar results were 
obtained from Western blotting analysis for Cox2 and iNos protein. Since Cox2 regulates the 
arachidonic acid cascade the downstream formation of prostaglandin E2 (PGE2) was analyzed 
by ELISA. As expected α-13‘-COOH, but also α-TOH, reduced LPS-induced production of PGE2. 
In parallel iNos regulates the production of nitric oxide from L-arginine. Since expression of 
iNos was blocked by α-13‘-COOH, the production of nitric oxide was also inhibited. In 
contrast no significant changes after α-TOH treatment occurred. The inflammatory response 
is mainly mediated by activation of transcription factor NFκB. However, neither α-13‘-COOH 
nor α-TOH blocked the LPS-induced translocation of the p65 subunit of NFκB into the 
nucleus. Therefore we suggest that modulation of the inflammatory response by 
α-13‘-COOH may be independent from translocation of the NFκB subunit p65. 
In summary LCMs of α-TOH modulate lipid metabolism and exhibit antiinflammatory 
properties more effectively and by involving different signaling pathways compared to the 
metabolic precursor α-TOH. We therefore suggest that the LCMs represent a new class of 
regulatory signaling molecules. With these results we achieved a decisive contribution to 
clarify the biological mode of action of vitamin E, which is not well understood yet despite 
many years of research. Therefore further investigations are necessary to unravel the mode 
of action of the newly identified physiological α-TOH-metabolites.  




Die Atherosklerose mit ihren Komplikationen Herzinfarkt und Schlaganfall zählt in westlichen 
Industrienationen zu den häufigsten Todesursachen. Im Jahre 2012 bedingten 
kardiovaskuläre Erkrankungen (CVD) ca. 40% aller Todesfälle in Deutschland (Statistisches 
Bundesamt 2012); die Tendenz ist steigend (HONARBAKHSH & SCHACHTER 2009). Vitamin E in der 
Prävention von CVD wurde erstmalig in den 1950er Jahren durch den Mediziner Dr. Even 
Shut beschrieben (CHAN 1998). Schon damals wurden die antioxidativen Eigenschaften des 
Vitamin E erkannt, die daraufhin in den folgenden Jahrzehnten im Fokus der Vitamin E-
Forschung standen. Zahlreiche in vitro und im Tiermodell durchgeführte Studien ließen einen 
positiven Effekt des Vitamin E hinsichtlich altersbedingter Erkrankungen, wie z.B. CVD, Krebs 
und Alzheimer, vermuten. Viele Wissenschaftler erhofften sich daher, diese Erkrankungen 
durch die nutritive Zufuhr oder die Supplementation mit Vitamin E in ihrer Entstehung zu 
unterdrücken oder zumindest deren Krankheitsverlauf mildern zu können. In den letzten 
Jahrzehnten wurden daher zahlreiche Humanstudien durchgeführt, die jedoch mit sehr 
unterschiedlichen Ergebnissen endeten. Trotz der in vitro gezeigten atheroprotektiven 
Eigenschaften (VAN DAM et al. 2003) hatte eine Supplementierung mit Vitamin E keinen 
eindeutig positiven Effekt auf die Prävalenz koronarer Herzerkrankungen (WALLERT et al. 
2014). Die teils kontroversen Ergebnisse der Humanstudien begründen sich nicht nur in sehr 
unterschiedlichen Studiendesigns (bspw. Größe und Art der Probandengruppen, Dosis, 
Dauer sowie Art der Vitamin E-Supplementation). Möglicherweise ist der Metabolismus von 
Vitamin E im menschlichen Organismus individuell sehr unterschiedlich. Die Bedeutung 
dieser Unterschiede für die Entstehung von Erkrankungen ist jedoch bis heute noch nicht 
vollständig verstanden. 
Vitamin E ist eine hauptsächlich aus α-, β-, γ-, δ-Isomeren der Tocopherole (TOH) und 
Tocotrienole bestehende Mischung. Die Isomere unterscheiden sich durch ihr 
Methylierungsmuster am Chromanolringsystem sowie der Sättigung der Seitenkette. 
Vitamin E wird im humanen Organismus in der Leber abgebaut. Dieser Katabolismus erfolgt 
in drei Kompartimenten: am endoplasmatischen Retikulum (ER), den Peroxisomen und den 
Mitochondrien. Am ER wird zunächst durch eine CYP4F2/CYP3A4-abhängige 
ω-Hydroxylierung der langkettige Metabolit (LCM) α-13‘-OH gebildet, gefolgt von einer 
α-Oxidation zu α-13‘-COOH. Weiterführend erfolgen zwei β-Oxidationsschritte in den 
Peroxisomen und drei in den Mitochondrien. Dies führt zum Abbau der Seitenkette und 
somit zur Bildung der mittelkettigen und schließlich der kurzkettigen wasserlöslichen 
Metabolite, die vorrangig mit dem Urin ausgeschieden werden. Bis heute wurden zahlreiche 
dieser Metabolite im humanen Organismus detektiert; physiologische und mögliche 
pathophysiologische Effekte dieser Metabolite sind jedoch weitgehend unbekannt.  
Es ist uns erstmalig gelungen, den LCM α-13‘-COOH im humanen Serum von gesunden 
Probanden mittels LC/MS-QTOF zu identifizieren. Durch eine Optimierung der 
Probenaufarbeitung hinsichtlich enzymatischer Verdauung und der verwendeten 
Extraktionsmittel konnten wir diesen LCM in nanomolaren Konzentrationen im Serum 
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detektieren. Nach einer einwöchigen Supplementation mit 1000 IU/d RRR-α-TOH konnte ein 
Anstieg von α-13‘-COOH um den Faktor fünf beobachtet werden. Wir vermuten weiterhin, 
dass die Bildung und Wirkung dieser LCMs individuell sehr unterschiedlich ist; dies könnte 
eine Erklärung für die kontroversen Ergebnisse der Humanstudien sein. Diese Daten geben 
erste Hinweise auf eine mögliche physiologische Relevanz des Metaboliten α-13‘-COOH. 
Neben der Wirkung als Antioxidans besitzt Vitamin E auch nicht-antioxidative Eigenschaften 
(AZZI et al. 1995). Wir untersuchten daher die LCMs des α-TOHs, welche aus der 
afrikanischen Bitternuss garcinia kola synthetisiert werden, im Hinblick auf diese 
unabhängigen Eigenschaften. Makrophagen sind von besonderer Bedeutung für 
inflammatorische Prozesse und die Atherosklerose. Daher wurden in der vorliegenden Arbeit 
humane und murine Makrophagen verwendet, um neue Wirkmechanismen von Vitamin E 
und seinen Metaboliten zu untersuchen. 
Für das Aufrechterhalten der Lipidhomöostase spielt der scavenger-Rezeptor CD36 aufgrund 
seiner Beteiligung an der Aufnahme modifizierter Lipoproteine eine entscheidende Rolle 
(DEVARAJ et al. 2001). Mittels quantitativer Echtzeit-RT-PCR (RT-qPCR) und 
Durchflusszytometrie konnte gezeigt werden, dass die Expression von CD36-mRNA 
und -Protein durch α-13‘-OH und α-13‘-COOH signifikant induziert wird, wohingegen die 
Ausgangssubstanz α-TOH eine Senkung bewirkt. Eine Vorinkubation mit den LCMs gefolgt 
von einer zeitgleichen Applikation der Metabolite mit oxLDL zeigte eine signifikante additive 
Steigerung der CD36-Proteinexpression, wohingegen die Inkubation mit α-TOH keine 
Veränderung der oxLDL-induzierten CD36-Proteinexpression ergab. Ein weiterer 
Mechanismus für die Aufnahme von modifizierten LDL ist die Phagozytose. In Phagozytose-
Assays mit fluoreszenzmarkierten Mikropartikeln konnte mittels Durchflusszytometrie 
gezeigt werden, dass auch hier eine konträre Regulation zu α-TOHs erfolgt (IZGÜT-UYSAL et al. 
2004), die LCM inhibieren die Phagozytose. Trotz der induzierten CD36-Expression senken 
die LCMs jedoch im Vergleich zu α-TOH die Aufnahme von fluoreszenzmarkierten oxLDL 
sowie die Akkumulation von Neutrallipiden. Möglicherweise erfolgt eine Kompensation der 
CD36-vermittelten Aufnahme von oxLDL durch die verminderte Phagozytose (WALLERT et al. 
2013 // 2014).  
Neben der Schaumzellbindung sind Entzündungsreaktionen entscheidend für die Initiation 
und Progression der Atherosklerose. Durch Untersuchungen der Genexpression mittels 
RT-qPCR konnten wir zeigen, dass die Stimulation der Inflammationsmarker 
Cyclooxygenase 2 (Cox2) und induzierbare Stickstoffmonoxid-Synthase (iNos) durch 
bakterielle Lipopolysaccharide (LPS) durch α-13‘-COOH signifikant gehemmt werden, jedoch 
nicht durch α-TOH. Dieser Befund spiegelt sich auch auf Proteinebene wieder. Da die Cox2 
die Arachidonsäure-Kaskade reguliert, ist eine Regulation der Cox2-Proteinmenge mit der 
Produktion von Prostaglandin E2 (PGE2) assoziiert. ELISA bestätigten, dass α-13‘-COOH, aber 
auch α-TOH, die LPS-induzierte Produktion von PGE2 signifikant hemmen. Parallel dazu 
reguliert die iNos die Produktion von Stickstoffmonoxid aus L-Arginin. Wie zu erwarten führt 
die Hemmung der iNos-Proteinmenge zu einer signifikanten Hemmung der Produktion von 
Stickstoffmonoxid durch α-13‘-COOH, jedoch nicht durch α-TOH. Ein zentraler Regulator 
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inflammatorischer Prozesse ist der Transkriptionsfaktor NFκB. Daher wurde der Einfluss auf 
die Translokation der p65-Untereinheit von NFκB in den Zellkern untersucht. Weder durch 
α-13‘-COOH noch durch α-TOH konnte die LPS-induzierte Translokation der 
p65-Untereinheit geblockt werden. Daher ist zu vermuten, dass α-13‘-COOH die durch 
LPS-stimulierte Entzündungsreaktion unabhängig von der Translokation der NFκB 
p65-Untereinheit hemmt. 
Zusammenfassend kann festgestellt werden, dass die langkettigen Metabolite, bezogen auf 
den Lipidstoffwechsel und ihre antiinflammatorische Wirkung, biologisch deutlich aktiver als 
der metabolische Ausgangsstoff α-TOH sind. Weiterhin erfolgt die Vermittlung dieser athero-
protektiven Effekte vermutlich über andere Signalwege als im Fall von α-TOH. Ferner deuten 
weitere Ergebnisse dieser Doktorarbeit darauf hin, dass die α-LCM eine neue Klasse von 
regulatorisch wirkenden Signalmolekülen darstellen könnten. Mit diesen Ergebnissen könnte 
ein entscheidender neuer Beitrag zur weiterführenden Aufklärung der biologischen Funktion 
von Vitamin E erzielt werden. Trotz jahrzehntelanger Forschung ist diese nach wie vor nicht 
eindeutig geklärt. Weiterführende Experimente sind nun notwendig, um die den 
Beobachtungen zugrundliegenden Wirkmechanismen der α-LCM aufzuklären.  
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